USD860451S1 - Implant removal tool - Google Patents

Implant removal tool Download PDF

Info

Publication number
USD860451S1
USD860451S1 US29/566,822 US201629566822F USD860451S US D860451 S1 USD860451 S1 US D860451S1 US 201629566822 F US201629566822 F US 201629566822F US D860451 S USD860451 S US D860451S
Authority
US
United States
Prior art keywords
removal tool
implant removal
implant
design
view
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US29/566,822
Inventor
Jay S. Smith
Michael R. Cole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Priority to US29/566,822 priority Critical patent/USD860451S1/en
Assigned to INTARCIA THERAPEUTICS INC. reassignment INTARCIA THERAPEUTICS INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COLE, MICHAEL R., SMITH, JAY S.
Priority to AU201710849F priority patent/AU201710849S/en
Priority to AU201710851F priority patent/AU201710851S/en
Priority to AU201616506F priority patent/AU201616506S/en
Priority to AU201710850F priority patent/AU201710850S/en
Priority to AU201710852F priority patent/AU201710852S/en
Priority to AU201710853F priority patent/AU201710853S/en
Priority to CA175047F priority patent/CA175047S/en
Priority to CA175048F priority patent/CA175048S/en
Priority to CA171754F priority patent/CA171754S/en
Priority to JPD2017-12969F priority patent/JP1596822S/ja
Priority to JPD2016-26195F priority patent/JP1593290S/ja
Priority to JPD2017-12968F priority patent/JP1596821S/ja
Priority to US29/699,323 priority patent/USD912249S1/en
Publication of USD860451S1 publication Critical patent/USD860451S1/en
Application granted granted Critical
Assigned to MIDCAP FINANCIAL TRUST, AS AGENT reassignment MIDCAP FINANCIAL TRUST, AS AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INTARCIA IRELAND LIMITED, INTARCIA THERAPEUTICS, INC.
Assigned to BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT reassignment BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C., AS COLLATERAL AGENT SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INTARCIA THERAPEUTICS, INC.
Assigned to INTARCIA THERAPEUTICS, INC. reassignment INTARCIA THERAPEUTICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: BAUPOST PRIVATE INVESTMENTS BVIV-3, L.L.C. AS COLLATERAL AGENT
Assigned to INTARCIA THERAPEUTICS, INC., INTARCIA IRELAND LIMITED reassignment INTARCIA THERAPEUTICS, INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: MIDCAP FINANCIAL TRUST, AS AGENT
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Description

FIG. 1 is a perspective view of an embodiment of a design for an implant removal tool;
FIG. 2 is a front view of the design for the implant removal tool of FIG. 1;
FIG. 3 is a back view of the design for the implant removal tool of FIG. 1;
FIG. 4 is a first side view of the design for the implant removal tool of FIG. 1;
FIG. 5 is a second side view of the design for the implant removal tool of FIG. 1;
FIG. 6 is a top view for the design for the implant removal tool of FIG. 1;
FIG. 7 is a bottom view for the design of the implant removal tool of FIG. 1;
FIG. 8 is a perspective view of another embodiment of a design for an implant removal tool;
FIG. 9 is a front view of the design for the implant removal tool of FIG. 8;
FIG. 10 is a back view of the design for the implant removal tool of FIG. 8;
FIG. 11 is a first side view of the design for the implant removal tool of FIG. 8;
FIG. 12 is a second side view of the design for the implant removal tool of FIG. 8;
FIG. 13 is a top view for the design for the implant removal tool of FIG. 8; and,
FIG. 14 is a bottom view for the design of the implant removal tool of FIG. 8.
Any broken lines shown in the drawings form no part of the claimed design.

Claims (1)

    CLAIM
  1. The ornamental design for an implant removal tool, as shown and described.
US29/566,822 2016-06-02 2016-06-02 Implant removal tool Active USD860451S1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
US29/566,822 USD860451S1 (en) 2016-06-02 2016-06-02 Implant removal tool
AU201710849F AU201710849S (en) 2016-06-02 2016-11-21 Implant removal tool
AU201710851F AU201710851S (en) 2016-06-02 2016-11-21 Implant removal tool
AU201616506F AU201616506S (en) 2016-06-02 2016-11-21 Implant removal tool
AU201710850F AU201710850S (en) 2016-06-02 2016-11-21 Implant removal tool
AU201710852F AU201710852S (en) 2016-06-02 2016-11-21 Implant removal tool
AU201710853F AU201710853S (en) 2016-06-02 2016-11-21 Implant removal tool
CA175047F CA175047S (en) 2016-06-02 2016-11-23 Implant removal tool
CA175048F CA175048S (en) 2016-06-02 2016-11-23 Implant removal tool
CA171754F CA171754S (en) 2016-06-02 2016-11-23 Implant removal tool
JPD2017-12969F JP1596822S (en) 2016-06-02 2016-12-02
JPD2016-26195F JP1593290S (en) 2016-06-02 2016-12-02
JPD2017-12968F JP1596821S (en) 2016-06-02 2016-12-02
US29/699,323 USD912249S1 (en) 2016-06-02 2019-07-24 Implant removal tool

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29/566,822 USD860451S1 (en) 2016-06-02 2016-06-02 Implant removal tool

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US29/699,323 Division USD912249S1 (en) 2016-06-02 2019-07-24 Implant removal tool

Publications (1)

Publication Number Publication Date
USD860451S1 true USD860451S1 (en) 2019-09-17

Family

ID=59505946

Family Applications (2)

Application Number Title Priority Date Filing Date
US29/566,822 Active USD860451S1 (en) 2016-06-02 2016-06-02 Implant removal tool
US29/699,323 Active USD912249S1 (en) 2016-06-02 2019-07-24 Implant removal tool

Family Applications After (1)

Application Number Title Priority Date Filing Date
US29/699,323 Active USD912249S1 (en) 2016-06-02 2019-07-24 Implant removal tool

Country Status (4)

Country Link
US (2) USD860451S1 (en)
JP (3) JP1596821S (en)
AU (6) AU201710850S (en)
CA (3) CA175048S (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD933219S1 (en) * 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Citations (792)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1655158A (en) 1926-09-08 1928-01-03 Radium Emanation Corp Instrument for implanting radon seeds
FR640907A (en) 1927-06-25 1928-07-24 Automatic flow limiter
DE635692C (en) 1936-09-22 Herbert Zadow Medical syringe
US2110208A (en) 1937-02-12 1938-03-08 U S Standard Products Company Antigen preparations
US2168437A (en) 1935-04-10 1939-08-08 Kenneth O Buercklin Injection device
US2531724A (en) 1948-09-20 1950-11-28 Edmund D Cevasco Infant bath mat
US2643653A (en) 1951-07-19 1953-06-30 Heidrich John Pill injector
US3016895A (en) 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
US3025991A (en) 1960-05-23 1962-03-20 Carron Products Co Bottle stopper
US3122162A (en) 1963-06-20 1964-02-25 Asa D Sands Flow control device
GB1049104A (en) 1963-05-11 1966-11-23 Prodotti Antibiotici Spa Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3463157A (en) * 1966-07-14 1969-08-26 Donald W Hunt Artery compression clamp
US3523906A (en) 1962-07-11 1970-08-11 Gevaert Photo Prod Nv Process for encapsulating water and compounds in aqueous phase by evaporation
US3538916A (en) 1968-12-19 1970-11-10 Joseph S Wiles Injection pistol
US3620216A (en) 1969-06-25 1971-11-16 Abbott Lab Implant trocar
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3632768A (en) 1969-10-02 1972-01-04 Upjohn Co Therapeutic composition and method for treating infections with actinospectacin
US3669104A (en) 1970-06-15 1972-06-13 Pfizer Implant gun
US3691090A (en) 1969-01-16 1972-09-12 Fuji Photo Film Co Ltd Encapsulation method
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US3737337A (en) 1970-03-04 1973-06-05 Bayer Ag Process for the production of microgranulates
US3766915A (en) 1971-12-21 1973-10-23 Illinois Tool Works Plastic needle holder
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3869549A (en) 1972-02-17 1975-03-04 Ciba Geigy Corp Injectable oily peptide preparations and processes for their manufacture
US3891570A (en) 1972-01-26 1975-06-24 Toyo Jozo Kk Process for preparing microcapsules
US3960757A (en) 1973-06-27 1976-06-01 Toyo Jozo Co., Ltd. Process for encapsulation of medicaments
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
GB1518683A (en) 1974-07-05 1978-07-19 Sandoz Ltd Pharmaceutical compositions
US4105030A (en) 1977-01-03 1978-08-08 Syntex (U.S.A.) Inc. Implant apparatus
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4203439A (en) 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4221862A (en) 1975-06-27 1980-09-09 Fuji Photo Film Co., Ltd. Method of producing finely divided polymer particles
US4223674A (en) 1978-06-29 1980-09-23 Arthur J. McIntosh Implant gun
US4243030A (en) 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
USD258837S (en) 1977-10-17 1981-04-07 Gambro Dialysatoren Gmbh And Co. Kg Dialyzer cartridge
USD259458S (en) 1978-06-09 1981-06-09 Fuller Charles R Support pad for an infant
US4305927A (en) 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4373527A (en) 1979-04-27 1983-02-15 The Johns Hopkins University Implantable, programmable medication infusion system
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
EP0079405A1 (en) 1980-07-23 1983-05-25 Corless, Marion Apparatus for improving blood sugar control in diabetics
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4444498A (en) 1981-02-27 1984-04-24 Bentley Laboratories Apparatus and method for measuring blood oxygen saturation
US4451253A (en) 1980-12-18 1984-05-29 Harman Sherman M Means and method for administering medicinals
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
US4455143A (en) 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4552561A (en) 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4588614A (en) 1981-10-20 1986-05-13 Adnovum Ag Pseudoplastic gel transfer
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US4597753A (en) 1983-04-21 1986-07-01 Hundon Forge Limited Implanting method and device
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4655462A (en) 1985-01-07 1987-04-07 Peter J. Balsells Canted coiled spring and seal
US4657533A (en) * 1986-05-01 1987-04-14 Oscarsson Rolf A Hypodermic injector device
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
US4675184A (en) 1981-11-28 1987-06-23 501 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
EP0254394A1 (en) 1986-06-16 1988-01-27 Alza Corporation Dosage form for delivering a drug comprising solubility regulating member
US4727138A (en) 1981-10-19 1988-02-23 Genentech, Inc. Human immune interferon
US4734284A (en) 1985-02-19 1988-03-29 Nippon Kayaku Kabushiki Kaisha Etoposide preparations
US4737437A (en) 1986-03-27 1988-04-12 East Shore Chemical Co. Light sensitive diazo compound, composition and method of making the composition
US4743449A (en) 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
EP0295411A1 (en) 1987-05-15 1988-12-21 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
FR2616665A2 (en) 1987-03-16 1988-12-23 Denance Raymond Stabiliser adaptor for hypodermic needle, for adjusting penetration as a function of the angle of attack, formed from a needle guard
EP0304107A1 (en) 1987-08-18 1989-02-22 Akzo N.V. Implant injection device
US4818517A (en) 1986-01-24 1989-04-04 Akzo N.V. Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US4820267A (en) 1985-02-19 1989-04-11 Endocon, Inc. Cartridge injector for pellet medicaments
US4820638A (en) 1982-05-28 1989-04-11 Dr. Karl Thomae Gmbh Novel alpha interferon species produced by recombinant means
US4826144A (en) 1988-04-25 1989-05-02 Peter J. Balsells Inside back angle canted coil spring
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US4830344A (en) 1988-04-25 1989-05-16 Peter J. Balsells Canted-coil spring with turn angle and seal
US4834708A (en) 1987-03-31 1989-05-30 George Pillari Puncture needle assembly
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4871094A (en) 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US4873080A (en) 1983-06-08 1989-10-10 Dr. Karl Thomae Gmbh Oral anti-diabetic pharmaceutical compositions and the preparation thereof
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4876781A (en) 1988-04-25 1989-10-31 Peter J. Balsells Method of making a garter-type axially resilient coiled spring
US4882166A (en) 1981-09-30 1989-11-21 National Research Development Corporation Compositions comprising encapsulated particles and their preparation
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US4893795A (en) 1988-08-15 1990-01-16 Peter J. Balsells Radially loaded canted coiled spring with turn angle
US4907788A (en) 1988-04-25 1990-03-13 Peter J. Balsells Dual concentric canted-coil spring apparatus
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4915366A (en) 1988-04-25 1990-04-10 Peter J. Balsells Outside back angle canted coil spring
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4917887A (en) 1986-03-10 1990-04-17 Boehringer Ingelheim International Gmbh Hybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
JPH02124814A (en) 1988-07-05 1990-05-14 Takeda Chem Ind Ltd Sustained release microcapsule containing water-soluble drug
EP0368339A2 (en) 1988-11-11 1990-05-16 Eisai Co., Ltd. Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US4934666A (en) 1988-04-25 1990-06-19 Peter J. Balsells Coiled spring electromagnetic shielding gasket
EP0373867A1 (en) 1988-12-13 1990-06-20 Alza Corporation Delivery system comprising means for governing fluid ingress into the system
US4940588A (en) 1984-10-30 1990-07-10 Elan Corporation Controlled release powder and process for its preparation
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
EP0379147A2 (en) 1989-01-17 1990-07-25 Sterling Winthrop Inc. Extrudable elastic gel for use as carrier for therapeutic agent
US4957119A (en) 1987-08-08 1990-09-18 Akzo N.V. Contraceptive implant
US4961253A (en) 1988-04-25 1990-10-09 Peter J. Balsells Manufacturing method for canted-coil spring with turn angle and seal
US4964204A (en) 1988-04-25 1990-10-23 Peter J. Balsells Method for making a garter-type axially-resilient coil spring
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
WO1990013780A1 (en) 1989-05-01 1990-11-15 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
WO1990013285A1 (en) 1989-05-01 1990-11-15 Enzytech, Inc. Process for producing small particles of biologically active molecules
NL8901004A (en) 1989-04-21 1990-11-16 Nedap Nv Positioning attachment for animal implanting or injecting tool - has automatically shaped transparent positioning piece with adjustable needle insertion depth
NL9000948A (en) 1989-04-21 1990-11-16 Nedap Nv Injection and implanting instrument for coding or numbering animals - has handle sliding on guide pin with insertion depth stop parallel to hollow needle and anatomically shaped locating plate
US4974821A (en) 1988-04-25 1990-12-04 Peter J. Balsells Canted-coil spring with major axis radial loading
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US4994028A (en) 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5019382A (en) 1986-11-06 1991-05-28 The Texas A&M University System Treatment of immuno-resistant disease with low-dose interferon
WO1991007160A1 (en) 1989-11-13 1991-05-30 Medicorp Holding S.A. Storage bottle containing a constituent of a medicinal solution
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
EP0431942A2 (en) 1989-12-06 1991-06-12 Sansho Co., Ltd. Percutaneously absorbable pharmaceutical preparation containing dopamine derivative
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5053014A (en) 1990-02-01 1991-10-01 Critikon, Inc. Catheter with controlled valve
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5056718A (en) 1987-11-13 1991-10-15 Wakefield Anthony W Jetting nozzle
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5066436A (en) 1989-01-04 1991-11-19 Gist-Brocades N.V. Process for microencapsulation
US5072070A (en) 1989-12-01 1991-12-10 Peter J. Balsells Device for sealing electromagnetic waves
US5071642A (en) 1986-10-23 1991-12-10 Dr. Rentschler Arzneimittel Gmbh & Co. Dihydropyridine containing compositions
US5079388A (en) 1989-12-01 1992-01-07 Peter J. Balsells Gasket for sealing electromagnetic waves
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5090962A (en) 1989-04-28 1992-02-25 Flp Enterprises, Inc. Non-reusable syringe
US5108078A (en) 1988-04-25 1992-04-28 Peter J. Balsells Canted-coil spring loaded while in a cavity
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5113938A (en) 1991-05-07 1992-05-19 Clayton Charley H Whipstock
US5117066A (en) 1988-04-25 1992-05-26 Peter J. Balsells Retaining and locking electromagnetic gasket
EP0486959A1 (en) 1990-11-22 1992-05-27 Vectorpharma International S.P.A. Pharmaceutical composition of microparticles with controlled release and process of preparing it
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
USD326718S (en) 1989-12-26 1992-06-02 Minnesota Mining And Manufacturing Co. Blood sensor cassette
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5122128A (en) 1990-03-15 1992-06-16 Alza Corporation Orifice insert for a ruminal bolus
US5122377A (en) 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5134244A (en) 1988-04-25 1992-07-28 Peter J. Balsells Electromagnetic shielding seal for rotary/reciprocating shaft
EP0497575A1 (en) 1991-01-30 1992-08-05 Texas Instruments Holland B.V. Injector
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
USD329278S (en) 1990-10-01 1992-09-08 Gallup Allen I Infant's bathing support
US5147295A (en) 1991-01-23 1992-09-15 Ideal Instruments, Inc. Retractable implanter
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5160122A (en) 1990-03-20 1992-11-03 Peter J. Balsells Coil spring with an elastomer having a hollow coil cross section
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5161806A (en) 1990-12-17 1992-11-10 Peter J. Balsells Spring-loaded, hollow, elliptical ring seal
WO1992019241A1 (en) 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5192273A (en) 1989-07-24 1993-03-09 Steven F. Bierman Catheterization system
WO1993006821A1 (en) 1991-10-04 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
WO1993006819A1 (en) 1991-10-10 1993-04-15 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5203849A (en) 1990-03-20 1993-04-20 Balsells Peter J Canted coil spring in length filled with an elastomer
US5204108A (en) 1987-10-10 1993-04-20 Danbiosyst Uk Ltd. Transmucosal formulations of low molecular weight peptide drugs
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
WO1993008832A1 (en) 1991-11-08 1993-05-13 Dallas Biotherapeutics, Inc. Stabilization of human interferon
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5213809A (en) 1990-01-24 1993-05-25 Alza Corporation Delivery system comprising means for controlling internal pressure
WO1993009763A1 (en) 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5250026A (en) 1992-05-27 1993-10-05 Destron/Idi, Inc. Adjustable precision transponder injector
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
WO1993023083A1 (en) 1992-05-11 1993-11-25 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
USD342855S (en) 1992-11-20 1994-01-04 Butler Ii George D Combined infant cushion and cover
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US5279554A (en) 1990-02-09 1994-01-18 Rhone Merieux Implanting device
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5279608A (en) 1990-12-18 1994-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Osmotic pumps
US5279555A (en) 1992-08-24 1994-01-18 Merck & Co., Inc. Device for injecting implants
US5284655A (en) 1989-09-21 1994-02-08 Osteotech, Inc. Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects
US5288501A (en) 1991-07-04 1994-02-22 Merz + Co. Gmbh & Co. Mechanically-stable, readily-disintegratable tablets made of small preformed particles containing active ingredients
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5290271A (en) 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
WO1994009743A1 (en) 1992-11-05 1994-05-11 R.P. Scherer Corporation Vented capsule
EP0596161A1 (en) 1992-11-06 1994-05-11 Texas Instruments Incorporated Apparatus for subcutaneous introduction of a needle
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1994010982A1 (en) 1992-11-17 1994-05-26 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5336505A (en) 1989-08-28 1994-08-09 Pharmaceutical Delivery Systems Bioerodible polymers useful for the controlled release of therapeutic agents
US5336057A (en) 1991-09-30 1994-08-09 Nippon Densan Corporation Micropump with liquid-absorptive polymer gel actuator
US5348544A (en) 1993-11-24 1994-09-20 Becton, Dickinson And Company Single-handedly actuatable safety shield for needles
WO1994021262A1 (en) 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
US5352662A (en) 1991-10-01 1994-10-04 Brooks Norman D Injectable extended release formulations and methods
US5368863A (en) 1990-01-24 1994-11-29 Alza Corporation Long-term delivery device with early startup
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
EP0631794A1 (en) 1993-06-23 1995-01-04 Hoechst Aktiengesellschaft Device for administering implants
WO1995001167A2 (en) 1993-06-25 1995-01-12 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5395319A (en) 1991-03-06 1995-03-07 Suddeutsche Feinmechanik Gmbh Needle for inserting an object into the body
WO1995009007A1 (en) 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US5413672A (en) 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
USD358644S (en) 1994-01-18 1995-05-23 Bio Medic Data Systems, Inc. Transponder implanter
WO1995013799A1 (en) 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5428024A (en) 1992-02-28 1995-06-27 Collagen Corporation High concentration homogenized collagen compositions
US5429602A (en) 1992-04-29 1995-07-04 Hauser; Jean-Luc Programmable portable infusion pump system
JPH07196479A (en) 1994-01-04 1995-08-01 Unitika Ltd Method for producing microcapsule
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5445829A (en) 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
WO1995034285A1 (en) 1994-06-13 1995-12-21 Alza Corporation Dosage form for administering drug in liquid formulation
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5484403A (en) 1994-04-05 1996-01-16 Avid Marketing, Inc. Hypodermic syringe for implanting solid objects
WO1996001134A1 (en) 1994-07-01 1996-01-18 Alza Corporation Osmotic system for delivering of fluid-sensitive somatotropin to bovine animals
US5486365A (en) 1993-09-17 1996-01-23 Fuji Chemical Industry Co., Ltd. Calcium hydrogen phosphate, a method for preparing it, and an excipient utilizing it
WO1996003116A1 (en) 1994-07-25 1996-02-08 Alkermes Controlled Therapeutics, Inc. Controlled release of metal cation-stabilized interferon
US5498255A (en) 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5511355A (en) 1991-11-15 1996-04-30 Dingler; Gerhard Construction element
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5514110A (en) 1993-03-22 1996-05-07 Teh; Eutiquio L. Automatic flow control device
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5541172A (en) 1991-06-28 1996-07-30 Endorecherche, Inc. Controlled release systems and low dose androgens
US5540912A (en) 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5542682A (en) 1995-03-27 1996-08-06 American Variseal Slant coil spring and seal
US5543156A (en) 1991-01-09 1996-08-06 Alza Corporation Bioerodible devices and compositions for diffusional release of agents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0729747A1 (en) 1995-03-03 1996-09-04 L'oreal Use of amphiphilic compounds as thickening agent of non aqueous media and composition obtained
US5556642A (en) 1992-07-16 1996-09-17 Tanabe Seiyaku Co., Ltd. Method for producing sustained release microsphere preparation
US5557318A (en) 1994-07-12 1996-09-17 Koninklijke Ptt Nederland N.V. Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5558637A (en) 1993-10-13 1996-09-24 Leiras Oy Implant injection device
US5569289A (en) 1993-06-24 1996-10-29 Yoon; Inbae Safety penetrating instrument with penetrating member and cannula moving during penetration and triggered safety member protusion
US5571525A (en) 1992-03-30 1996-11-05 Alza Corporation Erosion rate modifier for use in bioerodible drug delivery devices and method of use
US5574137A (en) 1983-12-16 1996-11-12 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
WO1996036317A1 (en) 1995-05-18 1996-11-21 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
WO1996039142A1 (en) 1995-06-06 1996-12-12 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
WO1996040049A1 (en) 1995-06-07 1996-12-19 Alza Corporation Peptide/protein suspended formulations
WO1996040355A1 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
WO1996040139A1 (en) 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide
US5589167A (en) 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5602010A (en) 1986-12-10 1997-02-11 Boehringer Ingelheim International Gmbh DNA encoding equine-gamma interferon and recombinant production of equine IFN-γ polypeptides
US5605688A (en) 1984-12-18 1997-02-25 Boehringer Ingelheim International Gmbh Recombinant dog and horse type I interferons
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5614221A (en) 1989-10-23 1997-03-25 Medivent Method of preparing a drug delivery system comprising a drug and a gel using a syringe
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5613954A (en) 1994-11-21 1997-03-25 Stryker Corporation Laparoscopic surgical Y-tube cannula
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5620698A (en) 1995-03-06 1997-04-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amido groups
US5620705A (en) 1994-08-04 1997-04-15 Alza Corporation Progestin tablet
WO1997015296A1 (en) 1995-10-23 1997-05-01 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
WO1997015289A1 (en) 1995-10-25 1997-05-01 Cortecs (Uk) Limited Solubilisation methods
EP0771817A2 (en) 1995-10-30 1997-05-07 Laboratorios S.A.L.V.A.T., S.A. Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight
US5630796A (en) 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
US5635213A (en) 1992-11-30 1997-06-03 Neopharma Production Ab Pharmaceutical formulation
US5639477A (en) 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
US5639640A (en) 1983-11-02 1997-06-17 Genzyme Corporation DNA encoding the beta subunit of human follide stimulating hormone and expression vectors and cells containing same
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5654010A (en) 1992-12-02 1997-08-05 Alkermes, Inc. Composition for sustained release of human growth hormone
WO1997028181A2 (en) 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US5660861A (en) 1994-04-28 1997-08-26 Alza Corporation Effective therapy for epilepsies
WO1997031943A1 (en) 1996-03-01 1997-09-04 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US5668170A (en) 1994-07-13 1997-09-16 Alza Corporation Composition and method enhancing transdermal electrotransport agent delivery
JPH09241153A (en) 1996-03-04 1997-09-16 Q P Corp Lipid emulsion for intravenous injection
JPH09509346A (en) 1994-02-25 1997-09-22 ズードドイッチェ・フアインメハニーク・ゲーエムベーハー Cannula for subcutaneous fixation of target
US5672549A (en) 1996-01-31 1997-09-30 Sumitomo Bakelite Company Limited Method of producing epoxy resin-encapsulated semiconductor device
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
WO1997041837A2 (en) 1996-05-07 1997-11-13 Alkermes Controlled Therapeutics Inc. Ii Microparticles
US5688801A (en) 1993-11-19 1997-11-18 Janssen Pharmaceutica Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US5690925A (en) 1983-12-16 1997-11-25 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
WO1997044039A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US5695463A (en) 1994-09-27 1997-12-09 Societe De Conseils De Recherches Et D'applications Safety injection device
WO1997046204A2 (en) 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
US5697113A (en) 1995-03-23 1997-12-16 Aminach Bedding & Furniture Manufacturing Ltd. Ventilated infant's mattress
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5697914A (en) 1995-03-16 1997-12-16 Becton Dickinson And Company Control forward/flashback forward one hand introducer needle and catheter assembly
WO1997047339A1 (en) 1996-06-14 1997-12-18 Filtertek, S.A. Gravity infusion set for medical infusions
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
WO1998000158A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998000152A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
WO1998000157A1 (en) 1996-07-03 1998-01-08 Alza Corporation Aqueous formulations of peptides
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1998002169A2 (en) 1996-07-15 1998-01-22 Alza Corporation Novel formulations for the administration of fluoxetine
US5711967A (en) 1991-06-17 1998-01-27 Spirig Ag, Pharmazeutische Praeparate Oral diclofenac preparation
US5713847A (en) 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
WO1998007412A1 (en) 1996-08-21 1998-02-26 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
US5725497A (en) 1995-06-07 1998-03-10 American Cyanamid Company Injection dart system
US5728396A (en) 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
WO1998013092A1 (en) 1996-09-27 1998-04-02 American Home Products Corporation Tissue penetration guide
WO1998013091A1 (en) 1996-09-27 1998-04-02 American Home Products Corporation Medical device for the placement of solid materials
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5738845A (en) 1989-03-02 1998-04-14 The Women's Research Institute Human interferon τ proteins and methods of use
WO1998016250A1 (en) 1996-10-16 1998-04-23 Alza Corporation Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
WO1998017315A2 (en) 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO1998020930A1 (en) 1996-11-15 1998-05-22 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
WO1998027960A2 (en) 1996-12-20 1998-07-02 Bioglan Ireland (R & D) Limited A nitroimidazole gel composition
WO1998027962A2 (en) 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US5782396A (en) 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
WO1998032463A2 (en) 1997-01-28 1998-07-30 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
US5795779A (en) 1982-11-01 1998-08-18 Berlex Laboratories, Inc. Human interferon-β (IFN-β) produced in Chinese hamster ovary (CHO) cells
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US5814323A (en) 1995-10-16 1998-09-29 Lever Brothers Company, Division Of Conopco, Inc. Cosmetic composition
WO1998042317A2 (en) 1997-03-24 1998-10-01 Alza Corporation Implantable delivery device with self adjustable exit port
US5817129A (en) 1996-10-31 1998-10-06 Ethicon, Inc. Process and apparatus for coating surgical sutures
USD399821S (en) 1997-11-07 1998-10-20 Motorola, Inc. Front section of a battery charger
US5827297A (en) 1992-10-01 1998-10-27 Medicamat S.A. Device for transplanting small diameter hair grafts
WO1998047487A1 (en) 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US5830501A (en) 1991-12-06 1998-11-03 Alza Corporation Dosage form comprising hydrophilic polymer
US5836935A (en) 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
WO1998051282A1 (en) 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Solid porous matrices and methods of making and using the same
US5843891A (en) 1993-04-28 1998-12-01 Sherman; Bernard C. Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
US5844017A (en) 1995-03-06 1998-12-01 Ethicon, Inc. Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5851451A (en) 1995-12-15 1998-12-22 Takeda Chemical Industries, Ltd. Production of microspheres
WO1998058698A1 (en) 1997-06-20 1998-12-30 Akzo Nobel N.V. Preloaded implantation device
US5859150A (en) 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US5858746A (en) 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
WO1999003453A1 (en) 1997-07-14 1999-01-28 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov , D.D. Novel pharmaceutical formulation with controlled release of active substances
WO1999004768A2 (en) 1997-07-25 1999-02-04 Alza Corporation Osmotic delivery system flow modulator apparatus
WO1999004659A1 (en) 1997-07-24 1999-02-04 Evgeni Gennadievich Durnev Child bib containing an absorbing substance (material)
WO1999004767A2 (en) 1997-07-25 1999-02-04 Alza Corporation Osmotic delivery system with semipermeable plug
US5874388A (en) 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
WO1999012549A2 (en) 1997-09-09 1999-03-18 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Controlled release microsphere delivery system
WO1999016419A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
USD408917S (en) 1998-02-26 1999-04-27 Minnesota Mining And Manufacturing Company Membrane support structure of a flow through cell for blood gas measurement
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5906816A (en) 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5906599A (en) 1995-11-09 1999-05-25 Intermed, Inc. Device for delivering biological agents
WO1999025728A1 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999029306A1 (en) 1997-12-12 1999-06-17 Biohybrid Technologies, Inc. Devices for cloaking transplanted cells
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
WO1999033449A1 (en) 1997-12-30 1999-07-08 Alza Corporation Beneficial agent delivery system with membrane plug
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
WO1999039700A1 (en) 1998-02-06 1999-08-12 Eurand International S.P.A. Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5948430A (en) 1996-11-11 1999-09-07 Lts Lohmann Therapie-Systeme Gmbh Water soluble film for oral administration with instant wettability
US5951521A (en) 1998-09-25 1999-09-14 Minimed Inc. Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US5962023A (en) 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
USD415073S (en) 1998-08-17 1999-10-12 ScooterBug, Inc. Stroller
US5972373A (en) 1995-05-02 1999-10-26 Taisho Pharmaceutical Co., Ltd. Taste masking pharmaceutical composition for oral administration
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5984890A (en) 1996-09-27 1999-11-16 American Home Products Corporation Medical device for the placement of solid materials
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999062501A1 (en) 1998-05-29 1999-12-09 Sumitomo Pharmaceuticals Company, Limited Controlled release preparations having multi-layer structure
WO1999064061A1 (en) 1998-06-12 1999-12-16 Bionebraska, Inc. GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6022561A (en) 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations
US6023802A (en) 1997-09-10 2000-02-15 King; Susan Melton Infant sleeper
US6029361A (en) 1998-03-25 2000-02-29 Ultratech Stepper, Inc. Air-guage nozzle probe structure for microlithographic image focusing
WO2000013663A1 (en) 1998-09-09 2000-03-16 Alza Corporation Dosage form comprising liquid formulation
US6053927A (en) 1998-10-15 2000-04-25 Rsh-Gs Trust Apparatus and method for implant removal
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US6069133A (en) 1996-03-14 2000-05-30 The Immune Response Corporation Targeted delivery of genes encoding interferon
US6074660A (en) 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US6074377A (en) 1996-10-10 2000-06-13 Sanfilippo, Ii; Dominic Joseph Method of installing vascular access device
WO2000039280A2 (en) 1998-12-31 2000-07-06 Viragen, Inc. Leukocyte-derived interferon preparations
WO2000038652A1 (en) 1998-12-23 2000-07-06 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
WO2000041548A2 (en) 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US6100346A (en) 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
WO2000045790A2 (en) 1999-02-08 2000-08-10 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
USD430671S (en) 1999-05-10 2000-09-05 Shute Wallace B Obstetrical forceps
US6120787A (en) 1995-10-19 2000-09-19 Biogram Ab Sustained release particles
WO2000054745A2 (en) 1999-03-18 2000-09-21 Durect Corporation Devices and methods for pain management
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
WO2000059476A1 (en) 1999-04-05 2000-10-12 Pharmaceutical Discovery Corporation Methods for fine powder formation
US6133429A (en) 1997-10-03 2000-10-17 Becton Dickinson And Company Chromophores useful for the preparation of novel tandem conjugates
US6133249A (en) 1995-12-19 2000-10-17 Macnaught Medical Pty Limited Phospholipid and propylene glycol based lubricant
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
EP1046399A1 (en) 1999-04-19 2000-10-25 Schering Corporation HCV combination therapy, containing ribavirin in association with antioxidants
WO2000066087A2 (en) 1999-05-03 2000-11-09 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2000066138A2 (en) 1999-04-30 2000-11-09 Bionebraska, Inc. Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
US6147168A (en) 1995-03-06 2000-11-14 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US6146139A (en) 1999-06-01 2000-11-14 Harrison, Iii; Louis V. Forceps apparatus
WO2000067728A2 (en) 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US6191102B1 (en) 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
US6190700B1 (en) 1995-12-15 2001-02-20 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
US6190350B1 (en) 1997-12-29 2001-02-20 Alza Corporation Implanter device for subcutaneous implants
US6190702B1 (en) 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO2001019345A1 (en) 1999-09-10 2001-03-22 Astrazeneca Ab Method to obtain microparticles
US6217908B1 (en) 1992-04-24 2001-04-17 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6217893B1 (en) 1997-04-18 2001-04-17 Pharma Biotech Sustained-release compositions and method for preparing same
US6218431B1 (en) 1996-07-31 2001-04-17 Bayer Corporation Substituted biphenyls
WO2001028631A1 (en) 1999-10-15 2001-04-26 Deschutes Medical Products, Inc. Brachytherapy instrument and methods
WO2001028525A2 (en) 1999-10-21 2001-04-26 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
US6248112B1 (en) 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
WO2001043528A2 (en) 1999-12-17 2001-06-21 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
US6258377B1 (en) 1996-07-02 2001-07-10 Provalis Uk Limited Hydrophobic preparations containing medium chain monoglycerides
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
WO2001051041A1 (en) 2000-01-13 2001-07-19 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
USD445975S1 (en) 1999-08-27 2001-07-31 Black & Decker, Inc. Base unit for a hand held vacuum cleaner
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US20010012511A1 (en) 1995-03-06 2001-08-09 Bezwada Rao S. Method of preventing adhesions with absorbable polyoxaesters
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
WO2001068168A1 (en) 2000-03-13 2001-09-20 Leiras Oy Device for inserting implants
US20010031790A1 (en) 1999-12-22 2001-10-18 Beisswenger Paul J. Treatment for complications of type 2 diabetes
US20010031940A1 (en) 2000-03-23 2001-10-18 Hans-Joachim Loos Device for administering implants
WO2001078683A2 (en) 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
US20010036472A1 (en) 1998-12-17 2001-11-01 Wong Patrick S.-L. Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US20010040326A1 (en) 1999-06-14 2001-11-15 Lord Corporation Resilient member with deformed element and method of forming same
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US20020004481A1 (en) 1997-06-13 2002-01-10 Jeffrey L. Cleland Controlled release microencapsulated ngf formulation
US20020012818A1 (en) 2000-01-19 2002-01-31 Sakari Ruppi Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US20020037309A1 (en) 2000-08-10 2002-03-28 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
WO2002028366A2 (en) 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
US6372218B1 (en) 1986-11-06 2002-04-16 The Texas A&M University System Interferon dosage form and method therefor
US6375978B1 (en) 1997-12-22 2002-04-23 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US20020048600A1 (en) 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
WO2002036072A2 (en) 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
WO2002043800A2 (en) 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
US6402716B1 (en) 1998-02-20 2002-06-11 Lg Chemical Ltd. Syringe assembly
WO2002045752A2 (en) 2000-12-08 2002-06-13 Leo Pharma A/S Dermal anti-inflammatory composition
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US20020077599A1 (en) 2000-12-19 2002-06-20 Animas Corporation Transcutaneous inserter for low-profile infusion sets
US20020098180A1 (en) 2000-03-24 2002-07-25 Huan-Yao Lei Fullerene pharmaceutical compositions for preventing or treating disorders
US6428517B1 (en) 1999-05-10 2002-08-06 Milestone Scientific, Inc. Hand-piece for injection device with a retractable and rotating needle
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
WO2002067895A2 (en) 2000-11-16 2002-09-06 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
WO2002069983A1 (en) 2001-03-01 2002-09-12 Bharat Serums & Vaccines Ltd. Amphotericin b aqueous composition
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US20020136848A1 (en) 1998-03-12 2002-09-26 Fumio Yoshii Lactone-containing resin composition, molded object thereof, and film
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20020141985A1 (en) 2000-12-14 2002-10-03 Amylin Parmaceuticals, Inc. Peptide YY and peptide YY agonists for treatment of metabolic disorders
WO2002076344A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US6461605B1 (en) 1995-11-02 2002-10-08 Schering Corporation Continuous low-dose cytokine infusion therapy
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
WO2002083216A1 (en) 2001-04-13 2002-10-24 Becton Dickinson And Company Method of intradermally injecting substances
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
WO2002085428A2 (en) 2001-04-19 2002-10-31 Microsolutions, Inc. Implantable osmotic pump
US6478768B1 (en) 1997-08-08 2002-11-12 Gaplast Gmbh Implant syringe
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20020197185A1 (en) 2001-06-20 2002-12-26 Jamiolkowski Dennis D. Antimicrobial coatings for medical devices
WO2003000230A1 (en) 2001-06-22 2003-01-03 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030007992A1 (en) 2001-06-22 2003-01-09 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6508808B1 (en) 1999-12-21 2003-01-21 Alza Corporation Valve for osmotic devices
WO2003007981A1 (en) 2001-07-20 2003-01-30 Intermune, Inc. Methods of treating liver fibrosis
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
WO2003011892A2 (en) 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
US6528093B1 (en) 1992-12-07 2003-03-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US20030045454A1 (en) 2001-06-21 2003-03-06 Franklin Okumu Sustained release formulation
WO2003020245A1 (en) 2001-08-31 2003-03-13 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
WO2003024503A2 (en) 2001-09-17 2003-03-27 Durect Corporation Device and method for accurate delivery of an active agent
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
USD472896S1 (en) 2000-12-23 2003-04-08 Andreas Peiker Telephone support
US6544239B2 (en) 1998-10-16 2003-04-08 Bio-Plexus Delaware, Inc. Releasable locking needle assembly with optional release accessory therefor
US6544252B1 (en) 1998-12-31 2003-04-08 Alza Corporation Osmotic delivery system having space efficient piston
EP1300129A2 (en) 1997-12-29 2003-04-09 Alza Corporation Implant vial
US6547250B1 (en) 2000-08-21 2003-04-15 Westport Research Inc. Seal assembly with two sealing mechanisms for providing static and dynamic sealing
WO2003030923A1 (en) 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US20030078616A1 (en) 2000-12-14 2003-04-24 Core Medical, Inc. Plug with detachable guidewire element and methods for use
US20030078618A1 (en) 2001-10-19 2003-04-24 Fey Kate E. System and method for removing implanted devices
WO2003041684A2 (en) 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
US20030097121A1 (en) 2001-10-24 2003-05-22 Claude Jolly Implantable fluid delivery apparatuses and implantable electrode
WO2003041757A2 (en) 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
US6569420B2 (en) 1997-12-08 2003-05-27 Genentech, Inc. Human interferon-ε: a type I interferon
US20030104063A1 (en) 2001-06-22 2003-06-05 Babcock Walter C. Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
US20030108609A1 (en) 1999-02-08 2003-06-12 Berry Stephen A. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030108608A1 (en) 2001-12-12 2003-06-12 Erik Laridon Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
US6579851B2 (en) 2000-03-14 2003-06-17 Amylin Pharmaceuticals, Inc. Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
EP1323450A1 (en) 2001-12-18 2003-07-02 Risdon Pharma GmbH Syringe device
WO2003053400A1 (en) 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
US6589157B2 (en) 2000-05-18 2003-07-08 Integrated Implant Systems, L.L.C. Drive mechanism for medical instrument
US6592508B1 (en) 1995-12-18 2003-07-15 Integrated Implant Systems, Llc Fiberoptic-guided interstitial seed manual applicator and seed cartridge
US20030135153A1 (en) 2001-12-17 2003-07-17 Charles Hagemeier Drug implant injection device
US20030138491A1 (en) 2000-02-10 2003-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
WO2003066585A2 (en) 2002-02-08 2003-08-14 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US6607529B1 (en) 1995-06-19 2003-08-19 Medtronic Vidamed, Inc. Electrosurgical device
US20030157178A1 (en) 2001-11-14 2003-08-21 Guohua Chen Injectable depot composition
WO2003072113A1 (en) 2002-02-28 2003-09-04 Norbrook Laboratories Limited Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
WO2003072133A2 (en) 2002-02-28 2003-09-04 Norferm Da Immunostimulatory agent comprising a biomass of methanotrophic bacterium
US6626863B1 (en) 2000-11-22 2003-09-30 Nusaf, L.L.C. Safety syringe
US20030186858A1 (en) 2000-01-31 2003-10-02 Arentsen Anne Charlotte Crystallisation of a GLP-1 analogue
US20030191099A1 (en) 2001-11-27 2003-10-09 Schering Ag 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
US6645192B2 (en) 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
US20030211974A1 (en) 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US20030215515A1 (en) 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US20030220617A1 (en) 2002-05-22 2003-11-27 C. Dickerson Co. Safety needle introducer and universal needle protector for vascular access devices
US20030233101A1 (en) 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US6670368B1 (en) 1999-04-06 2003-12-30 Astrazeneca Ab Pyrimidine compounds with pharmaceutical activity
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20040001689A1 (en) 2002-06-28 2004-01-01 Intel Corporation System and method for improving audio during post-production of video recordings
US20040002442A1 (en) 2001-10-05 2004-01-01 Clark Pan Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US20040024069A1 (en) 2002-07-31 2004-02-05 Guohua Chen Injectable depot compositions and uses thereof
US20040024068A1 (en) 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
US20040022859A1 (en) 2002-07-31 2004-02-05 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
US20040029784A1 (en) 2002-01-22 2004-02-12 Hathaway David R. Methods and compositions for treating polycystic ovary syndrome
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6706689B2 (en) 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
WO2004026106A2 (en) 2002-09-18 2004-04-01 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
WO2004036186A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
WO2004034975A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
US20040097906A1 (en) 2002-06-17 2004-05-20 Fereira Pamela J. Osmotic delivery system with early zero order push power engine
US20040102762A1 (en) 2002-11-21 2004-05-27 Gilbert Scott Jay Osmotic delivery device having a two-way valve and dynamically self-adjusting flow channel
US20040101557A1 (en) 1995-06-07 2004-05-27 Gibson John W. High viscosity liquid controlled delivery system and medical or surgical device
WO2004056338A2 (en) 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
USD492995S1 (en) * 2003-04-03 2004-07-13 Valera Pharmaceuticals, Inc. Implanting device
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20040142867A1 (en) 2003-01-14 2004-07-22 Kiyomoto Oi Stabilized proteinic preparation
US6767887B1 (en) 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
US20040151753A1 (en) 2002-11-06 2004-08-05 Guohua Chen Controlled release depot formulations
US20040199140A1 (en) 2003-04-03 2004-10-07 Rue Matthew L. Implanting device and method of using same
US20040198654A1 (en) 2001-08-23 2004-10-07 Wolfgang Glaesner Glucagon-like peptide-1analogs
WO2004089335A2 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20040209801A1 (en) 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040215133A1 (en) 2002-09-18 2004-10-28 Allergan, Inc. Apparatus for delivery of ocular implants
US20040225113A1 (en) 1998-07-21 2004-11-11 Lafleur David W. Keratinocyte derived interferon
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US20040266683A1 (en) 2002-12-17 2004-12-30 Hathaway David R Prevention and treatment of cardiac arrhythmias
US20040266692A1 (en) 1996-08-08 2004-12-30 Young Andrew A. Exendin pharmaceutical compositions
US20040265273A1 (en) 1997-04-28 2004-12-30 Hong Li Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
US20050004557A1 (en) 2003-06-12 2005-01-06 Russell Scott M. Orifice device having multiple channels with varying flow rates for drug delivery
US20050010942A1 (en) 2003-07-09 2005-01-13 Samsung Electronics Co., Ltd. Optical disc drive
US20050010196A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
US20050009742A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US20050070927A1 (en) 2003-09-30 2005-03-31 Feinberg Marc E. Tissue approximation device
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US20050079202A1 (en) 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US20050079200A1 (en) 2003-05-16 2005-04-14 Jorg Rathenow Biocompatibly coated medical implants
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20050095284A1 (en) 2003-10-31 2005-05-05 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
US20050101943A1 (en) 2003-11-06 2005-05-12 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050112188A1 (en) 2003-11-17 2005-05-26 Eliaz Rom E. Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US6899898B2 (en) 2000-12-21 2005-05-31 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US20050131386A1 (en) 2003-12-15 2005-06-16 Freeman Lynetta J. Method and device for minimally invasive implantation of biomaterial
US20050143749A1 (en) 2003-12-31 2005-06-30 Depuy Spine, Inc. Inserter instrument and implant clip
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050216087A1 (en) 2004-01-05 2005-09-29 St. Francis Medical Technologies, Inc. Disk repair structures for positioning disk repair material
US20050215475A1 (en) 2003-05-30 2005-09-29 John Ong Transmucosal delivery of peptides and proteins
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
WO2005102293A1 (en) 2004-04-15 2005-11-03 Amylin Pharmaceuticals, Inc. Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20060014678A1 (en) 2002-06-28 2006-01-19 Imperial College Innovations Ltd. Modification of feeding behavior
US20060030526A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable suspension formulations of erythropoietin receptor agonists
WO2006023526A2 (en) 2004-08-18 2006-03-02 Waters Investments Limited Defined leak path for high pressure seal
US7008439B1 (en) 1990-09-21 2006-03-07 Datascope Investments Corp. Device and method for sealing puncture wounds
US20060069029A1 (en) 1999-01-14 2006-03-30 Kolterman Orville G Exendin analog formulations
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US20060073182A1 (en) 2004-10-01 2006-04-06 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060084604A1 (en) 2004-10-19 2006-04-20 Chieko Kitaura Transepithelial delivery of peptides with incretin hormone activities
US20060084922A1 (en) 2002-09-04 2006-04-20 Ruark Botha Device for securing a blood vessel cannula to a body
US20060094693A1 (en) 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US20060106399A1 (en) 2004-11-18 2006-05-18 Taras John S Drill guide tissue protector
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060160736A1 (en) 2004-12-30 2006-07-20 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
WO2006077242A1 (en) 2005-01-24 2006-07-27 N.V. Organon Applicator for inserting an implant
WO2006077250A1 (en) 2005-01-24 2006-07-27 N.V. Organon Applicator for inserting an implant
US7084243B2 (en) 2000-06-16 2006-08-01 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2006081279A2 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006084139A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc. An implantable interferon-containing device
US20060178304A1 (en) 2003-06-03 2006-08-10 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
JP2006213727A (en) 1993-04-07 2006-08-17 Scios Inc Sustained release of peptide
WO2006101815A2 (en) 2005-03-15 2006-09-28 Alza Corporation Pharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US20060233841A1 (en) 1999-06-04 2006-10-19 Brodbeck Kevin J Implantable gel compositions and method of manufacture
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US20060264890A1 (en) 2005-05-06 2006-11-23 Medtronic Minimed, Inc. Needle inserter and method for infusion device
US7141547B2 (en) 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
WO2006131730A1 (en) 2005-06-06 2006-12-14 Camurus Ab Glp-1 analogue formulations
US20060293232A1 (en) 2004-02-11 2006-12-28 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7163697B2 (en) 2001-06-22 2007-01-16 Johns Hopkins University School Of Medicine Biodegradable polymer compositions, compositions and uses related thereto
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007024700A2 (en) 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
WO2007056681A2 (en) 2005-11-04 2007-05-18 Smithkline Beecham Corporation Methods for administering hypoglycemic agents
US20070141102A1 (en) 2004-03-24 2007-06-21 N.V. Organon Drug delivery system based on polyethylene vinylacetate copolymers
US20070149011A1 (en) 2003-02-18 2007-06-28 Medconx, Inc. Male medical device electrical connector with engineered friction fit
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
US7241457B2 (en) 2003-09-30 2007-07-10 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
WO2007082889A1 (en) 2006-01-19 2007-07-26 N.V. Organon Kit for and method of assembling an applicator for inserting an implant
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
US20070248572A1 (en) 2001-11-09 2007-10-25 Intarica Therapeutics, Inc. Method for treating diseases with omega interferon
USD555589S1 (en) 2007-01-23 2007-11-20 Intec, Inc. Battery charger and game controller cradle
WO2007133778A2 (en) 2006-05-12 2007-11-22 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
US20070281024A1 (en) 2005-02-03 2007-12-06 Alza Corporation Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator
US20080020016A1 (en) 2006-07-11 2008-01-24 Quest Pharmaceutical Services, Llc Pharmaceutical compositions for sustained release delivery of peptides
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20080065090A1 (en) 1998-08-14 2008-03-13 Scribner Robert M Methods and apparatus for placing materials into bone
US20080064636A1 (en) 2003-01-10 2008-03-13 Imperial College Innovations Limited Modification of Feeding Behaviour
WO2008041245A2 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US20080208194A1 (en) 2007-02-13 2008-08-28 Christine Bickenbach Double cut shaver
US20080207512A1 (en) 2004-11-01 2008-08-28 Amylin Pharmaceuticals, Inc. Methods for Treating Obesity and Obesity Related and Disorders
US20080226689A1 (en) 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20080260840A1 (en) 2005-02-03 2008-10-23 Alessi Thomas R Suspension formulations of insulinotropic peptides and uses thereof
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20080269725A1 (en) 2005-07-22 2008-10-30 Trent Deem Osmotically Driven Dispense Pump and Related Components for Use in High Pressure Applications
WO2008134425A1 (en) 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US20080312157A1 (en) 2005-02-11 2008-12-18 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
US20090036364A1 (en) 2005-02-11 2009-02-05 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US20090074734A1 (en) 2006-05-02 2009-03-19 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US20090163447A1 (en) 2004-08-25 2009-06-25 Maggio Edward T Compositions for Drug Administration
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20090202608A1 (en) 2008-02-13 2009-08-13 Alessi Thomas R Devices, formulations, and methods for delivery of multiple beneficial agents
US20090202481A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US20090209460A1 (en) 2005-12-16 2009-08-20 Amylin Pharmaceuticals, Inc. Compositions and methods for treating obesity and related metabolic disorders
US20090210019A1 (en) 2008-02-14 2009-08-20 Dennis Dong-Won Kim Treatment of excess weight by neural downregulation in combination with compositions
WO2009109927A2 (en) 2008-03-05 2009-09-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
US7589169B2 (en) 2002-02-27 2009-09-15 Pharmain Corporation Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US20090234392A1 (en) 2008-03-13 2009-09-17 Depuy Spine, Inc. Method for inserting a spinal fixation element using implants having guide tabs
US20090254143A1 (en) 2008-04-04 2009-10-08 Tweden Katherine S Methods and systems for glucose regulation
US7604647B2 (en) 2004-10-22 2009-10-20 Medical Instrument Development Laboratories, Inc. Ophthalmic cannula insertion tool and method
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
WO2009143265A2 (en) 2008-05-20 2009-11-26 Charles Neill Stripping of heavier hydrocarbons from liquefied natural gas
US7632256B2 (en) 2006-10-24 2009-12-15 Mosler Theodore J Catheter gripping device
US20090312246A1 (en) 2005-08-19 2009-12-17 Amylin Pharmaceuticals, Inc. Uses of Glucoregulatory Proteins
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
USD608447S1 (en) 2005-01-14 2010-01-19 Edwards Lifesciences Corporation Sensor case
US7666835B2 (en) 2001-09-07 2010-02-23 Imperial Innovations Limited Oxyntomodulin for preventing or treating excess weight
US20100094252A1 (en) 2008-10-14 2010-04-15 Medtronic, Inc. Subcutaneous delivery tool
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100105627A1 (en) 2008-09-17 2010-04-29 Paul Salama Pharmaceutical compositions and related methods of delivery
US20100144621A1 (en) 2006-08-04 2010-06-10 Dennis Kim Use of Exendins and Exendin Agonists and GLP-1 Receptor Agonists for Altering the Concentration of Fibrinogen
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US7766924B1 (en) 1999-07-28 2010-08-03 Cardica, Inc. System for performing anastomosis
US7790140B2 (en) 2002-02-27 2010-09-07 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US20100298840A1 (en) 2009-05-22 2010-11-25 Schwartz Lyman D Phimosis Treatment Device and Method
US20100331878A1 (en) * 2009-06-25 2010-12-30 Carl Zeiss Surgical Gmbh Method and device for removing a balloon from a body cavity
US20100331868A1 (en) 2000-08-24 2010-12-30 Bardy Gust H Method For Constructing An Instrument With A Two-Part Plunger For Subcutaneous Implantation
WO2011011697A1 (en) 2009-07-23 2011-01-27 Sid Technologies, Llc Intradermal injection adapter
US7879794B2 (en) 2005-03-31 2011-02-01 Amylin Pharmaceuticals, Inc. Methods for controlling binge eating disorders
US20110076317A1 (en) 2009-09-28 2011-03-31 Alessi Thomas R Rapid establishment and/or termination of substantial steady-state drug delivery
US20110091527A1 (en) 2008-04-01 2011-04-21 Mosamedix B.V. Compositions and methods for reducing scar formation in wound healing
USD638478S1 (en) 2009-07-06 2011-05-24 Performance Designed Products Llc Video game controller accessory
US20110152182A1 (en) 2009-12-22 2011-06-23 Eli Lilly And Company Oxyntomodulin peptide analogue
US20110152181A1 (en) 2009-12-22 2011-06-23 Eli Lilly And Company Oxyntomodulin peptide analogue
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20110306549A1 (en) 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancreatitis
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8190702B1 (en) 2011-08-16 2012-05-29 Edgecast Networks, Inc. Systems and methods for invoking commands across a federation
US8202836B2 (en) 2005-03-09 2012-06-19 Imperial Innovations Limited Modified PYY (3-36) peptides and their effects on feeding behavior
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US8263736B2 (en) 2006-07-03 2012-09-11 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US8262667B1 (en) 2007-02-23 2012-09-11 Holmed Corporation Multi-diameter implant forceps
USD669589S1 (en) 2010-08-31 2012-10-23 Koninklijke Philips Electronics N.V. Blood system cartridge
US20120303045A1 (en) 2011-05-26 2012-11-29 Derm Instruments & Innovations Llc Skin removal instrument
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
USD678889S1 (en) 2011-10-04 2013-03-26 Avision Inc. Scanner docking station
US8454552B2 (en) 2000-08-24 2013-06-04 Cardiac Science Corporation Method for constructing an instrument with a covered bore for subcutaneous implantation
GB2501400A (en) 2012-04-19 2013-10-23 Removaid As Tool for removing a subcutaneous implant
WO2013160347A1 (en) 2012-04-24 2013-10-31 Urogyn B.V. Bulking agent applicator for treating female urinary incontinence
US20130296661A1 (en) 2012-05-04 2013-11-07 Pacesetter, Inc. System and method for implanting a physiologic sensor assembly
US20130324977A1 (en) 2012-06-04 2013-12-05 Medtronic, Inc. Transcutaneous implant tools, systems and methods
US20140058425A1 (en) 2012-08-27 2014-02-27 Amir Porat Manually operated surgical devices with operative portions formed of a see-through material
US20140121741A1 (en) 1998-06-03 2014-05-01 Spr Therapeutics, Llc Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
US8722037B2 (en) 2004-03-19 2014-05-13 Meck Sharp & Dohme B.V. X-ray visible drug delivery device
US8747412B2 (en) 2011-02-14 2014-06-10 Imds Corporation System and method for bone anchor removal
US20140236162A1 (en) 2013-02-19 2014-08-21 Mark Barongan Apparatus for Removing Devices Implanted in the Body
US8815802B2 (en) 2009-12-16 2014-08-26 Novo Nordisk A/S GLP-1 analogues and derivatives
US20140257272A1 (en) 2009-08-07 2014-09-11 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US8858621B2 (en) 2009-07-23 2014-10-14 Edwards Lifesciences Corporation Methods of implanting a prosthetic heart valve
US20140324067A1 (en) 2013-01-09 2014-10-30 Senseonics, Incorporated Subcutaneous tunneling and implantation tools for a disk-shaped sensor
US20150001118A1 (en) 2011-09-16 2015-01-01 Golden Aluminum, Inc. Application of designs to portion of food container
US20150133791A1 (en) 2012-05-29 2015-05-14 National University Corporation Kochi University Artery visualization device and artery imaging device
US9044209B2 (en) 2000-04-14 2015-06-02 Attenuex Technologies, Inc. Method of removing an inflated implant
US9078900B2 (en) 2008-09-30 2015-07-14 Braeburn Pharmaceuticals Bvba Sprl Implantable device for the delivery of risperidone and methods of use thereof
US20150297509A1 (en) 2012-11-19 2015-10-22 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions and methods of treatment thereof
US20150359553A1 (en) 2014-06-16 2015-12-17 Med-El Elektromedizinische Geraete Gmbh Implant magnet insertion and removal tools
US9241722B2 (en) 2012-10-08 2016-01-26 Warsaw Orthopedic, Inc. Surgical pin guide and methods of use
USD750764S1 (en) 2014-04-08 2016-03-01 Bootz Manufacturing Company Shower pan
US9332995B2 (en) 2012-09-25 2016-05-10 Russo Inventions, Llc Bone-harvesting tool
US20160158577A1 (en) * 2013-07-25 2016-06-09 Bruno ESCARGUEL Medical device for radiotherapy treatment
US20160354115A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
USD789540S1 (en) 2016-01-29 2017-06-13 Veterinary Implants Direct, Llc. Orthopedic plate
USD789539S1 (en) 2015-07-09 2017-06-13 Spinal Surgical Strategies, Llc Fusion cage
US20170273706A1 (en) 2016-03-24 2017-09-28 A.M. Surgical, Inc. Compact endoscopic surgical device and method of use thereof
USRE46577E1 (en) 2014-06-05 2017-10-24 Deka Products Limited Partnership Enclosure for a peritoneal dialysis device
US20180009871A1 (en) 2016-05-16 2018-01-11 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20180185451A1 (en) 2017-01-03 2018-07-05 Intarcia Therapeutics, Inc. Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug
US20180368875A1 (en) * 2016-05-25 2018-12-27 Nalu Medical, Inc. Methods and systems for insertion and fixation of implantable devices

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD271990S (en) 1981-09-17 1983-12-27 Arthur W. Pulfer Baby bath
US5276926A (en) 1992-08-04 1994-01-11 Raquel Lopez Baby bath and seat
JPH11100353A (en) 1997-09-29 1999-04-13 Esupo Kk Refined and deodorized liquid ester wax and its composition
US6224577B1 (en) 1998-03-02 2001-05-01 Medrad, Inc. Syringes and plungers for use therein
US6056718A (en) 1998-03-04 2000-05-02 Minimed Inc. Medication infusion set
US6395282B1 (en) 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
US6540950B1 (en) 2000-09-20 2003-04-01 Dahti, Inc. Carrier and attachment method for load bearing fabric
USD456776S1 (en) 2001-01-23 2002-05-07 Datex - Ohmeda, Inc. Snap sensor connector
WO2004099363A2 (en) 2003-05-01 2004-11-18 Medgenics Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US20120289859A9 (en) 2003-08-27 2012-11-15 Nicoson Zachary R System and method for minimally invasive disease therapy
US8845726B2 (en) 2006-10-18 2014-09-30 Vertiflex, Inc. Dilator
CN101790395B (en) 2007-04-23 2013-09-25 Sid科技有限责任公司 Methods and devices for intradermal injection
JP5328421B2 (en) 2009-02-27 2013-10-30 株式会社ホギメディカル forceps
USD791318S1 (en) 2009-09-14 2017-07-04 Bayer Oy Inserter
IT1396771B1 (en) 2009-10-23 2012-12-14 Surbone GUIDE TUBE FOR A TATTOO MACHINE NEEDLES
USD737972S1 (en) 2012-06-21 2015-09-01 Michael Chen Tattoo tube grip
US9452273B2 (en) 2012-11-28 2016-09-27 Richard M. Levitan Surgical device for cricothyrotomy and the like
USD825761S1 (en) 2015-04-24 2018-08-14 Otto Bock Healthcare Products Gmbh Part of prosthesis
US20180193059A1 (en) 2017-01-10 2018-07-12 Electronics And Telecommunications Research Institute Automatic hair follicle transplant apparatus
USD816843S1 (en) 2017-06-07 2018-05-01 Alevio, Llc Orthopedic implant

Patent Citations (1063)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE635692C (en) 1936-09-22 Herbert Zadow Medical syringe
US1655158A (en) 1926-09-08 1928-01-03 Radium Emanation Corp Instrument for implanting radon seeds
FR640907A (en) 1927-06-25 1928-07-24 Automatic flow limiter
US2168437A (en) 1935-04-10 1939-08-08 Kenneth O Buercklin Injection device
US2110208A (en) 1937-02-12 1938-03-08 U S Standard Products Company Antigen preparations
US2531724A (en) 1948-09-20 1950-11-28 Edmund D Cevasco Infant bath mat
US2643653A (en) 1951-07-19 1953-06-30 Heidrich John Pill injector
US3016895A (en) 1958-08-01 1962-01-16 Pan American Lab Inc Injector for subcutaneous implantation of solids
US3025991A (en) 1960-05-23 1962-03-20 Carron Products Co Bottle stopper
US3523906A (en) 1962-07-11 1970-08-11 Gevaert Photo Prod Nv Process for encapsulating water and compounds in aqueous phase by evaporation
GB1049104A (en) 1963-05-11 1966-11-23 Prodotti Antibiotici Spa Pharmaceutical compositions for oral or parenteral administration comprising tetracycline antibiotics
US3122162A (en) 1963-06-20 1964-02-25 Asa D Sands Flow control device
US3463157A (en) * 1966-07-14 1969-08-26 Donald W Hunt Artery compression clamp
US3538916A (en) 1968-12-19 1970-11-10 Joseph S Wiles Injection pistol
US3691090A (en) 1969-01-16 1972-09-12 Fuji Photo Film Co Ltd Encapsulation method
US3620216A (en) 1969-06-25 1971-11-16 Abbott Lab Implant trocar
US3632768A (en) 1969-10-02 1972-01-04 Upjohn Co Therapeutic composition and method for treating infections with actinospectacin
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3737337A (en) 1970-03-04 1973-06-05 Bayer Ag Process for the production of microgranulates
US3625214A (en) 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
US3669104A (en) 1970-06-15 1972-06-13 Pfizer Implant gun
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US4034756A (en) 1971-01-13 1977-07-12 Alza Corporation Osmotically driven fluid dispenser
US3732865A (en) 1971-01-13 1973-05-15 Alza Corp Osmotic dispenser
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3766915A (en) 1971-12-21 1973-10-23 Illinois Tool Works Plastic needle holder
US3891570A (en) 1972-01-26 1975-06-24 Toyo Jozo Kk Process for preparing microcapsules
US3869549A (en) 1972-02-17 1975-03-04 Ciba Geigy Corp Injectable oily peptide preparations and processes for their manufacture
US3797492A (en) 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3995632A (en) 1973-05-04 1976-12-07 Alza Corporation Osmotic dispenser
US3960757A (en) 1973-06-27 1976-06-01 Toyo Jozo Co., Ltd. Process for encapsulation of medicaments
GB1518683A (en) 1974-07-05 1978-07-19 Sandoz Ltd Pharmaceutical compositions
US4221862A (en) 1975-06-27 1980-09-09 Fuji Photo Film Co., Ltd. Method of producing finely divided polymer particles
US3987790A (en) 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4078060A (en) 1976-05-10 1978-03-07 Richardson-Merrell Inc. Method of inducing an estrogenic response
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4111203A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system with means for improving delivery kinetics of system
US4111201A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for delivering selected beneficial agents having varying degrees of solubility
US4203439A (en) 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4105030A (en) 1977-01-03 1978-08-08 Syntex (U.S.A.) Inc. Implant apparatus
USD258837S (en) 1977-10-17 1981-04-07 Gambro Dialysatoren Gmbh And Co. Kg Dialyzer cartridge
USD259458S (en) 1978-06-09 1981-06-09 Fuller Charles R Support pad for an infant
US4223674A (en) 1978-06-29 1980-09-23 Arthur J. McIntosh Implant gun
US4243030A (en) 1978-08-18 1981-01-06 Massachusetts Institute Of Technology Implantable programmed microinfusion apparatus
US4305927A (en) 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4373527A (en) 1979-04-27 1983-02-15 The Johns Hopkins University Implantable, programmable medication infusion system
US4373527B1 (en) 1979-04-27 1995-06-27 Univ Johns Hopkins Implantable programmable medication infusion system
US4310516A (en) 1980-02-01 1982-01-12 Block Drug Company Inc. Cosmetic and pharmaceutical vehicle thickened with solid emulsifier
US4384975A (en) 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
EP0079405A1 (en) 1980-07-23 1983-05-25 Corless, Marion Apparatus for improving blood sugar control in diabetics
US4350271A (en) 1980-08-22 1982-09-21 Alza Corporation Water absorbing fluid dispenser
US4376118A (en) 1980-10-06 1983-03-08 Miles Laboratories, Inc. Stable nonaqueous solution of tetracycline salt
US4389330A (en) 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
US4451253A (en) 1980-12-18 1984-05-29 Harman Sherman M Means and method for administering medicinals
US4340054A (en) 1980-12-29 1982-07-20 Alza Corporation Dispenser for delivering fluids and solids
US4444498A (en) 1981-02-27 1984-04-24 Bentley Laboratories Apparatus and method for measuring blood oxygen saturation
US4455145A (en) 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
US4474572A (en) 1981-09-29 1984-10-02 Syntex (U.S.A.) Inc. Implanting device and implant magazine
US4882166A (en) 1981-09-30 1989-11-21 National Research Development Corporation Compositions comprising encapsulated particles and their preparation
US4727138A (en) 1981-10-19 1988-02-23 Genentech, Inc. Human immune interferon
US4762791A (en) 1981-10-19 1988-08-09 Genentech, Inc. Human immune interferon
US4929554A (en) 1981-10-19 1990-05-29 Goeddel David V Human immune interferon
US4588614A (en) 1981-10-20 1986-05-13 Adnovum Ag Pseudoplastic gel transfer
US4675184A (en) 1981-11-28 1987-06-23 501 Sunstar Kabushiki Kaisha Pharmaceutical composition containing interferon in stable state
US5004689A (en) 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4455143A (en) 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4695623A (en) 1982-05-06 1987-09-22 Amgen Consensus human leukocyte interferon
US4897471A (en) 1982-05-06 1990-01-30 Amgen Consensus human leukocyte interferon
US4820638A (en) 1982-05-28 1989-04-11 Dr. Karl Thomae Gmbh Novel alpha interferon species produced by recombinant means
US4530840A (en) 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4753651A (en) 1982-08-30 1988-06-28 Alza Corporation Self-driven pump
US5795779A (en) 1982-11-01 1998-08-18 Berlex Laboratories, Inc. Human interferon-β (IFN-β) produced in Chinese hamster ovary (CHO) cells
US4552561A (en) 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4673405A (en) 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
GB2138298B (en) 1983-04-21 1986-11-05 Hundon Forge Ltd Pellet implanter
US4597753A (en) 1983-04-21 1986-07-01 Hundon Forge Limited Implanting method and device
US4639244A (en) 1983-05-03 1987-01-27 Nabil I. Rizk Implantable electrophoretic pump for ionic drugs and associated methods
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4873080A (en) 1983-06-08 1989-10-10 Dr. Karl Thomae Gmbh Oral anti-diabetic pharmaceutical compositions and the preparation thereof
US4743449A (en) 1983-09-12 1988-05-10 Fujisawa Pharmaceutical Co., Ltd. Drug-containing lipid vesicle preparation and method for preparing them
US4594108A (en) 1983-09-19 1986-06-10 The Dow Chemical Company Highly pseudoplastic polymer solutions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
US4840896A (en) 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4923805A (en) 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
US5767251A (en) 1983-11-02 1998-06-16 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
US5639640A (en) 1983-11-02 1997-06-17 Genzyme Corporation DNA encoding the beta subunit of human follide stimulating hormone and expression vectors and cells containing same
US5574137A (en) 1983-12-16 1996-11-12 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US5690925A (en) 1983-12-16 1997-11-25 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US4851228A (en) 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
US5120832A (en) 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US4927687A (en) 1984-10-01 1990-05-22 Biotek, Inc. Sustained release transdermal drug delivery composition
US5411951A (en) 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
US4940588A (en) 1984-10-30 1990-07-10 Elan Corporation Controlled release powder and process for its preparation
US4952402A (en) 1984-10-30 1990-08-28 Elan Corporation, P.L.C. Controlled release powder and process for its preparation
US5605688A (en) 1984-12-18 1997-02-25 Boehringer Ingelheim International Gmbh Recombinant dog and horse type I interferons
US4655462A (en) 1985-01-07 1987-04-07 Peter J. Balsells Canted coiled spring and seal
EP0521586A1 (en) 1985-01-30 1993-01-07 Applied Research Systems ARS Holding N.V. FSH and other recombinant hormones
US4734284A (en) 1985-02-19 1988-03-29 Nippon Kayaku Kabushiki Kaisha Etoposide preparations
US4820267A (en) 1985-02-19 1989-04-11 Endocon, Inc. Cartridge injector for pellet medicaments
US4609374A (en) 1985-04-22 1986-09-02 Alza Corporation Osmotic device comprising means for governing initial time of agent release therefrom
US4885166A (en) 1985-06-11 1989-12-05 Ciba-Geigy Corporation Hybrid interferons
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
US4818517A (en) 1986-01-24 1989-04-04 Akzo N.V. Pharmaceutical preparation for obtaining a highly viscose hydrogel or suspension
US4917887A (en) 1986-03-10 1990-04-17 Boehringer Ingelheim International Gmbh Hybrid interferons, their use as pharmaceutical compositions and as intermediate products for the preparation of antibodies and the use thereof and processes for preparing them
US4865845A (en) 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4737437A (en) 1986-03-27 1988-04-12 East Shore Chemical Co. Light sensitive diazo compound, composition and method of making the composition
US4657533A (en) * 1986-05-01 1987-04-14 Oscarsson Rolf A Hypodermic injector device
US7138486B2 (en) 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US6849708B1 (en) 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5958909A (en) 1986-05-05 1999-09-28 The General Hospital Corporation Insulinotropic hormones and uses thereof
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
EP0254394A1 (en) 1986-06-16 1988-01-27 Alza Corporation Dosage form for delivering a drug comprising solubility regulating member
US5071642A (en) 1986-10-23 1991-12-10 Dr. Rentschler Arzneimittel Gmbh & Co. Dihydropyridine containing compositions
US6372218B1 (en) 1986-11-06 2002-04-16 The Texas A&M University System Interferon dosage form and method therefor
US5019382A (en) 1986-11-06 1991-05-28 The Texas A&M University System Treatment of immuno-resistant disease with low-dose interferon
US5602010A (en) 1986-12-10 1997-02-11 Boehringer Ingelheim International Gmbh DNA encoding equine-gamma interferon and recombinant production of equine IFN-γ polypeptides
US4871094A (en) 1986-12-31 1989-10-03 Alcon Laboratories, Inc. Means and method for dispensing substances
US5371089A (en) 1987-02-26 1994-12-06 Senetek, Plc Method and composition for ameliorating the adverse effects of aging
FR2616665A2 (en) 1987-03-16 1988-12-23 Denance Raymond Stabiliser adaptor for hypodermic needle, for adjusting penetration as a function of the angle of attack, formed from a needle guard
US4994028A (en) 1987-03-18 1991-02-19 Endocon, Inc. Injector for inplanting multiple pellet medicaments
US4834708A (en) 1987-03-31 1989-05-30 George Pillari Puncture needle assembly
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
EP0295411A1 (en) 1987-05-15 1988-12-21 Sansho Co., Ltd. Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof
US4940465A (en) 1987-05-27 1990-07-10 Felix Theeuwes Dispenser comprising displaceable matrix with solid state properties
US4892778A (en) 1987-05-27 1990-01-09 Alza Corporation Juxtaposed laminated arrangement
US5023088A (en) 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US4874388A (en) 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4915949A (en) 1987-07-13 1990-04-10 Alza Corporation Dispenser with movable matrix comprising a plurality of tiny pills
US4957119A (en) 1987-08-08 1990-09-18 Akzo N.V. Contraceptive implant
EP0304107A1 (en) 1987-08-18 1989-02-22 Akzo N.V. Implant injection device
US4915954A (en) 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US4886668A (en) 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US5204108A (en) 1987-10-10 1993-04-20 Danbiosyst Uk Ltd. Transmucosal formulations of low molecular weight peptide drugs
WO1989003678A1 (en) 1987-10-30 1989-05-05 Stolle Research & Development Corporation Low residual solvent microspheres and microencapsulation process
US4917895A (en) 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US5056718A (en) 1987-11-13 1991-10-15 Wakefield Anthony W Jetting nozzle
US5117066A (en) 1988-04-25 1992-05-26 Peter J. Balsells Retaining and locking electromagnetic gasket
US4934666A (en) 1988-04-25 1990-06-19 Peter J. Balsells Coiled spring electromagnetic shielding gasket
US4907788A (en) 1988-04-25 1990-03-13 Peter J. Balsells Dual concentric canted-coil spring apparatus
US4830344A (en) 1988-04-25 1989-05-16 Peter J. Balsells Canted-coil spring with turn angle and seal
US4964204A (en) 1988-04-25 1990-10-23 Peter J. Balsells Method for making a garter-type axially-resilient coil spring
US4974821A (en) 1988-04-25 1990-12-04 Peter J. Balsells Canted-coil spring with major axis radial loading
US4915366A (en) 1988-04-25 1990-04-10 Peter J. Balsells Outside back angle canted coil spring
US5108078A (en) 1988-04-25 1992-04-28 Peter J. Balsells Canted-coil spring loaded while in a cavity
US4826144A (en) 1988-04-25 1989-05-02 Peter J. Balsells Inside back angle canted coil spring
US5134244A (en) 1988-04-25 1992-07-28 Peter J. Balsells Electromagnetic shielding seal for rotary/reciprocating shaft
US4961253A (en) 1988-04-25 1990-10-09 Peter J. Balsells Manufacturing method for canted-coil spring with turn angle and seal
US4876781A (en) 1988-04-25 1989-10-31 Peter J. Balsells Method of making a garter-type axially resilient coiled spring
US4931285A (en) 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5024842A (en) 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US5160743A (en) 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US5006346A (en) 1988-04-28 1991-04-09 Alza Corporation Delivery system
JPH02124814A (en) 1988-07-05 1990-05-14 Takeda Chem Ind Ltd Sustained release microcapsule containing water-soluble drug
US4893795A (en) 1988-08-15 1990-01-16 Peter J. Balsells Radially loaded canted coiled spring with turn angle
EP0368339A2 (en) 1988-11-11 1990-05-16 Eisai Co., Ltd. Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt
EP0373867A1 (en) 1988-12-13 1990-06-20 Alza Corporation Delivery system comprising means for governing fluid ingress into the system
US5320616A (en) 1988-12-13 1994-06-14 Alza Corporation Delivery system comprising first walled section and second walled section united by fusion, adhesion or telescopic engagement
US5059423A (en) 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5034229A (en) 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5728088A (en) 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5110596A (en) 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US4969884A (en) 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5234424A (en) 1988-12-28 1993-08-10 Alza Corporation Osmotically driven syringe
US4976966A (en) 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US5066436A (en) 1989-01-04 1991-11-19 Gist-Brocades N.V. Process for microencapsulation
EP0379147A2 (en) 1989-01-17 1990-07-25 Sterling Winthrop Inc. Extrudable elastic gel for use as carrier for therapeutic agent
US5738845A (en) 1989-03-02 1998-04-14 The Women's Research Institute Human interferon τ proteins and methods of use
US5942223A (en) 1989-03-02 1999-08-24 University Of Florida Antiviral therapy using ovine or bovine interferon-tau
US5219572A (en) 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
NL9000948A (en) 1989-04-21 1990-11-16 Nedap Nv Injection and implanting instrument for coding or numbering animals - has handle sliding on guide pin with insertion depth stop parallel to hollow needle and anatomically shaped locating plate
NL8901004A (en) 1989-04-21 1990-11-16 Nedap Nv Positioning attachment for animal implanting or injecting tool - has automatically shaped transparent positioning piece with adjustable needle insertion depth
US5090962A (en) 1989-04-28 1992-02-25 Flp Enterprises, Inc. Non-reusable syringe
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1990013780A1 (en) 1989-05-01 1990-11-15 Enzytech, Inc. Very low temperature casting of controlled release microspheres
WO1990013285A1 (en) 1989-05-01 1990-11-15 Enzytech, Inc. Process for producing small particles of biologically active molecules
US5407609A (en) 1989-05-04 1995-04-18 Southern Research Institute Microencapsulation process and products therefrom
WO1990013361A1 (en) 1989-05-04 1990-11-15 Southern Research Institute Improved encapsulation process and products therefrom
US5445829A (en) 1989-05-05 1995-08-29 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5126142A (en) 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5192273A (en) 1989-07-24 1993-03-09 Steven F. Bierman Catheterization system
US5225205A (en) 1989-07-28 1993-07-06 Debiopharm S.A. Pharmaceutical composition in the form of microparticles
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5336505A (en) 1989-08-28 1994-08-09 Pharmaceutical Delivery Systems Bioerodible polymers useful for the controlled release of therapeutic agents
US5112614A (en) 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5660847A (en) 1989-09-14 1997-08-26 Alza Corporation Implantable delivery dispenser comprising exit port
US5284655A (en) 1989-09-21 1994-02-08 Osteotech, Inc. Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects
US5614221A (en) 1989-10-23 1997-03-25 Medivent Method of preparing a drug delivery system comprising a drug and a gel using a syringe
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
WO1991007160A1 (en) 1989-11-13 1991-05-30 Medicorp Holding S.A. Storage bottle containing a constituent of a medicinal solution
US5072070A (en) 1989-12-01 1991-12-10 Peter J. Balsells Device for sealing electromagnetic waves
US5079388A (en) 1989-12-01 1992-01-07 Peter J. Balsells Gasket for sealing electromagnetic waves
EP0431942A2 (en) 1989-12-06 1991-06-12 Sansho Co., Ltd. Percutaneously absorbable pharmaceutical preparation containing dopamine derivative
US5030216A (en) 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
USD326718S (en) 1989-12-26 1992-06-02 Minnesota Mining And Manufacturing Co. Blood sensor cassette
US5368863A (en) 1990-01-24 1994-11-29 Alza Corporation Long-term delivery device with early startup
US5213809A (en) 1990-01-24 1993-05-25 Alza Corporation Delivery system comprising means for controlling internal pressure
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5053014A (en) 1990-02-01 1991-10-01 Critikon, Inc. Catheter with controlled valve
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5279554A (en) 1990-02-09 1994-01-18 Rhone Merieux Implanting device
US5478564A (en) 1990-02-22 1995-12-26 Teva Pharmaceutical Industries, Ltd. Preparation of microparticles for controlled release of water-soluble substances
US5122128A (en) 1990-03-15 1992-06-16 Alza Corporation Orifice insert for a ruminal bolus
US5203849A (en) 1990-03-20 1993-04-20 Balsells Peter J Canted coil spring in length filled with an elastomer
US5160122A (en) 1990-03-20 1992-11-03 Peter J. Balsells Coil spring with an elastomer having a hollow coil cross section
US5120306A (en) 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5207752A (en) 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5413572A (en) 1990-04-02 1995-05-09 Alza Corporation Osmotic dosage system for liquid drug delivery
US5324280A (en) 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5290271A (en) 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5234692A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234695A (en) 1990-07-24 1993-08-10 Eastman Kodak Company Water dispersible vitamin E composition
US7008439B1 (en) 1990-09-21 2006-03-07 Datascope Investments Corp. Device and method for sealing puncture wounds
USD329278S (en) 1990-10-01 1992-09-08 Gallup Allen I Infant's bathing support
US5300302A (en) 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5529914A (en) 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5312389A (en) 1990-10-29 1994-05-17 Felix Theeuwes Osmotically driven syringe with programmable agent delivery
US5151093A (en) 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5122377A (en) 1990-11-19 1992-06-16 A.H. Robins, Company, Incorporated Oral delivery system for veterinary drugs
EP0486959A1 (en) 1990-11-22 1992-05-27 Vectorpharma International S.P.A. Pharmaceutical composition of microparticles with controlled release and process of preparing it
US5700486A (en) 1990-11-22 1997-12-23 Vectorpharma International S.P.A. Pharmaceutical compositions in the form of particles suitable for the controlled release of pharmacologically active substances and process for preparing the same compositions
US5279544A (en) 1990-12-13 1994-01-18 Sil Medics Ltd. Transdermal or interdermal drug delivery devices
US5161806A (en) 1990-12-17 1992-11-10 Peter J. Balsells Spring-loaded, hollow, elliptical ring seal
US5279608A (en) 1990-12-18 1994-01-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Osmotic pumps
US5543156A (en) 1991-01-09 1996-08-06 Alza Corporation Bioerodible devices and compositions for diffusional release of agents
US5147295A (en) 1991-01-23 1992-09-15 Ideal Instruments, Inc. Retractable implanter
US5300079A (en) 1991-01-30 1994-04-05 Texas Instruments Incorporated Injector
US5443459A (en) 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5531736A (en) 1991-01-30 1996-07-02 Alza Corporation Osmotic device for delayed delivery of agent
EP0497575A1 (en) 1991-01-30 1992-08-05 Texas Instruments Holland B.V. Injector
NL9100160A (en) 1991-01-30 1992-08-17 Texas Instruments Holland INJECTOR.
US5395319A (en) 1991-03-06 1995-03-07 Suddeutsche Feinmechanik Gmbh Needle for inserting an object into the body
US5861166A (en) 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
WO1992019241A1 (en) 1991-05-07 1992-11-12 Dynagen, Inc. A controlled, sustained release delivery system for smoking cessation
US5113938A (en) 1991-05-07 1992-05-19 Clayton Charley H Whipstock
US5137727A (en) 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5711967A (en) 1991-06-17 1998-01-27 Spirig Ag, Pharmazeutische Praeparate Oral diclofenac preparation
US5190765A (en) 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US5252338A (en) 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5541172A (en) 1991-06-28 1996-07-30 Endorecherche, Inc. Controlled release systems and low dose androgens
US5288501A (en) 1991-07-04 1994-02-22 Merz + Co. Gmbh & Co. Mechanically-stable, readily-disintegratable tablets made of small preformed particles containing active ingredients
US5336057A (en) 1991-09-30 1994-08-09 Nippon Densan Corporation Micropump with liquid-absorptive polymer gel actuator
US5352662A (en) 1991-10-01 1994-10-04 Brooks Norman D Injectable extended release formulations and methods
WO1993006821A1 (en) 1991-10-04 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
WO1993006819A1 (en) 1991-10-10 1993-04-15 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5795591A (en) 1991-10-10 1998-08-18 Alza Corporation Osmotic drug delivery devices with hydrophobic wall materials
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
WO1993008832A1 (en) 1991-11-08 1993-05-13 Dallas Biotherapeutics, Inc. Stabilization of human interferon
WO1993009763A1 (en) 1991-11-15 1993-05-27 Isp Investments Inc. Pharmaceutical tablet with pvp having an enhanced drug dissolution rate
US5511355A (en) 1991-11-15 1996-04-30 Dingler; Gerhard Construction element
US5830501A (en) 1991-12-06 1998-11-03 Alza Corporation Dosage form comprising hydrophilic polymer
US5312390A (en) 1992-01-10 1994-05-17 Alza Corporation Osmotic device with delayed activation of drug delivery
US5223265A (en) 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5658593A (en) 1992-01-16 1997-08-19 Coletica Injectable compositions containing collagen microcapsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5209746A (en) 1992-02-18 1993-05-11 Alza Corporation Osmotically driven delivery devices with pulsatile effect
US5308348A (en) 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5456679A (en) 1992-02-18 1995-10-10 Alza Corporation Delivery devices with pulsatile effect
US5428024A (en) 1992-02-28 1995-06-27 Collagen Corporation High concentration homogenized collagen compositions
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5318558A (en) 1992-03-12 1994-06-07 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5221278A (en) 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
US5571525A (en) 1992-03-30 1996-11-05 Alza Corporation Erosion rate modifier for use in bioerodible drug delivery devices and method of use
US5540912A (en) 1992-03-30 1996-07-30 Alza Corporation Viscous suspensions of controlled-release drug particles
US5858746A (en) 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US6217908B1 (en) 1992-04-24 2001-04-17 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5429602A (en) 1992-04-29 1995-07-04 Hauser; Jean-Luc Programmable portable infusion pump system
WO1993023083A1 (en) 1992-05-11 1993-11-25 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
US5250026A (en) 1992-05-27 1993-10-05 Destron/Idi, Inc. Adjustable precision transponder injector
US5556642A (en) 1992-07-16 1996-09-17 Tanabe Seiyaku Co., Ltd. Method for producing sustained release microsphere preparation
US5413672A (en) 1992-07-22 1995-05-09 Ngk Insulators, Ltd. Method of etching sendust and method of pattern-etching sendust and chromium films
US5512293A (en) 1992-07-23 1996-04-30 Alza Corporation Oral sustained release drug delivery device
US5279555A (en) 1992-08-24 1994-01-18 Merck & Co., Inc. Device for injecting implants
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US5827297A (en) 1992-10-01 1998-10-27 Medicamat S.A. Device for transplanting small diameter hair grafts
WO1994009743A1 (en) 1992-11-05 1994-05-11 R.P. Scherer Corporation Vented capsule
EP0596161A1 (en) 1992-11-06 1994-05-11 Texas Instruments Incorporated Apparatus for subcutaneous introduction of a needle
WO1994010982A1 (en) 1992-11-17 1994-05-26 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5871778A (en) 1992-11-17 1999-02-16 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release microsphere preparation containing antipsychotic drug
US5656299A (en) 1992-11-17 1997-08-12 Yoshitomi Pharmaceutical Industries, Ltd. Sustained release microsphere preparation containing antipsychotic drug and production process thereof
USD342855S (en) 1992-11-20 1994-01-04 Butler Ii George D Combined infant cushion and cover
US5472708A (en) 1992-11-27 1995-12-05 Andrx Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5635213A (en) 1992-11-30 1997-06-03 Neopharma Production Ab Pharmaceutical formulation
US5667808A (en) 1992-12-02 1997-09-16 Alkermes, Inc. Composition for sustained release of human growth hormone
US5654010A (en) 1992-12-02 1997-08-05 Alkermes, Inc. Composition for sustained release of human growth hormone
US6528093B1 (en) 1992-12-07 2003-03-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5589167A (en) 1993-02-23 1996-12-31 Genentech, Inc. Excipient stabilization of polypeptides treated with organic solvents
US5368588A (en) 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1994021262A1 (en) 1993-03-17 1994-09-29 Alza Corporation Device for the transdermal administration of alprazolam
US5514110A (en) 1993-03-22 1996-05-07 Teh; Eutiquio L. Automatic flow control device
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
JP2006213727A (en) 1993-04-07 2006-08-17 Scios Inc Sustained release of peptide
US5630796A (en) 1993-04-08 1997-05-20 Oxford Biosciences Limited Method of delivering powder transdermally with needless injector
US5843891A (en) 1993-04-28 1998-12-01 Sherman; Bernard C. Pharmaceutical acceptable compositions containing an alcohol and a hydrophobic drug
EP0627231A2 (en) 1993-05-05 1994-12-07 Alza Corporation Delivery devices with pulsatile effect
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5639477A (en) 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
US5997902A (en) 1993-06-23 1999-12-07 Alza Corporation Ruminal drug delivery device
EP0631794A1 (en) 1993-06-23 1995-01-04 Hoechst Aktiengesellschaft Device for administering implants
US5569289A (en) 1993-06-24 1996-10-29 Yoon; Inbae Safety penetrating instrument with penetrating member and cannula moving during penetration and triggered safety member protusion
WO1995001167A2 (en) 1993-06-25 1995-01-12 Alza Corporation Incorporating poly-n-vinyl amide in a transdermal system
US5498255A (en) 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5486365A (en) 1993-09-17 1996-01-23 Fuji Chemical Industry Co., Ltd. Calcium hydrogen phosphate, a method for preparing it, and an excipient utilizing it
US5686097A (en) 1993-09-29 1997-11-11 Alza Corporation Monoglyceride/lactate ester permeation enhancer for codelivery of steroids
WO1995009006A1 (en) 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer
WO1995009007A1 (en) 1993-09-29 1995-04-06 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5558637A (en) 1993-10-13 1996-09-24 Leiras Oy Implant injection device
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5965168A (en) 1993-11-19 1999-10-12 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5770231A (en) 1993-11-19 1998-06-23 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles 1,2-benzisothiazoles
US5688801A (en) 1993-11-19 1997-11-18 Janssen Pharmaceutica Method of inhibiting neurotransmitter activity using microencapsulated 3-piperidiny2-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
WO1995013799A1 (en) 1993-11-19 1995-05-26 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5654008A (en) 1993-11-19 1997-08-05 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
US5348544A (en) 1993-11-24 1994-09-20 Becton, Dickinson And Company Single-handedly actuatable safety shield for needles
JPH07196479A (en) 1994-01-04 1995-08-01 Unitika Ltd Method for producing microcapsule
USD358644S (en) 1994-01-18 1995-05-23 Bio Medic Data Systems, Inc. Transponder implanter
US5540665A (en) 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US6022561A (en) 1994-02-04 2000-02-08 Scotia Lipidteknik Ab Bilayers preparations
US5713847A (en) 1994-02-09 1998-02-03 The University Of Iowa Research Foundation Human drug delivery device for tinnitus
US5810769A (en) 1994-02-25 1998-09-22 Suddeutsche Feinmechanik Gmbh Cannula for the subcutaneous deposition of an object
JPH09509346A (en) 1994-02-25 1997-09-22 ズードドイッチェ・フアインメハニーク・ゲーエムベーハー Cannula for subcutaneous fixation of target
US5458888A (en) 1994-03-02 1995-10-17 Andrx Pharmaceuticals, Inc. Controlled release tablet formulation
US6007805A (en) 1994-03-07 1999-12-28 Imperial College Of Science And Technology Use of interferon subtype alpha-8 (IFN-α8) to treat viral infections of the liver
US5484403A (en) 1994-04-05 1996-01-16 Avid Marketing, Inc. Hypodermic syringe for implanting solid objects
US5660861A (en) 1994-04-28 1997-08-26 Alza Corporation Effective therapy for epilepsies
WO1995034285A1 (en) 1994-06-13 1995-12-21 Alza Corporation Dosage form for administering drug in liquid formulation
WO1996001134A1 (en) 1994-07-01 1996-01-18 Alza Corporation Osmotic system for delivering of fluid-sensitive somatotropin to bovine animals
EP0767689A1 (en) 1994-07-01 1997-04-16 Alza Corporation Osmotic system for delivering of fluid-sensitive somatotropin to bovine animals
US5557318A (en) 1994-07-12 1996-09-17 Koninklijke Ptt Nederland N.V. Method and apparatus for permitting a viewer to scan through a plurality of video signals provided by a transmitter
US5668170A (en) 1994-07-13 1997-09-16 Alza Corporation Composition and method enhancing transdermal electrotransport agent delivery
WO1996003116A1 (en) 1994-07-25 1996-02-08 Alkermes Controlled Therapeutics, Inc. Controlled release of metal cation-stabilized interferon
US5620705A (en) 1994-08-04 1997-04-15 Alza Corporation Progestin tablet
US5633011A (en) 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5695463A (en) 1994-09-27 1997-12-09 Societe De Conseils De Recherches Et D'applications Safety injection device
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5595759A (en) 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5836935A (en) 1994-11-10 1998-11-17 Ashton; Paul Implantable refillable controlled release device to deliver drugs directly to an internal portion of the body
US5613954A (en) 1994-11-21 1997-03-25 Stryker Corporation Laparoscopic surgical Y-tube cannula
EP0729747A1 (en) 1995-03-03 1996-09-04 L'oreal Use of amphiphilic compounds as thickening agent of non aqueous media and composition obtained
US20010021377A1 (en) 1995-03-06 2001-09-13 Jamiolkowski Dennis D. Hydrogels containing absorbable polyoxaamides
US6403655B1 (en) 1995-03-06 2002-06-11 Ethicon, Inc. Method of preventing adhesions with absorbable polyoxaesters
US6251435B1 (en) 1995-03-06 2001-06-26 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5595751A (en) 1995-03-06 1997-01-21 Ethicon, Inc. Absorbable polyoxaesters containing amines and/or amido groups
US5620698A (en) 1995-03-06 1997-04-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amido groups
US5698213A (en) 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US20010012511A1 (en) 1995-03-06 2001-08-09 Bezwada Rao S. Method of preventing adhesions with absorbable polyoxaesters
US5464929A (en) 1995-03-06 1995-11-07 Ethicon, Inc. Absorbable polyoxaesters
US6100346A (en) 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
US5618552A (en) 1995-03-06 1997-04-08 Ethicon, Inc. Absorbable polyoxaesters
US5962023A (en) 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5648088A (en) 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5700583A (en) 1995-03-06 1997-12-23 Ethicon, Inc. Hydrogels of absorbable polyoxaesters containing amines or amido groups
US5844017A (en) 1995-03-06 1998-12-01 Ethicon, Inc. Prepolymers of absorbable polyoxaesters containing amines and/or amido groups
US5859150A (en) 1995-03-06 1999-01-12 Ethicon, Inc. Prepolymers of absorbable polyoxaesters
US6147168A (en) 1995-03-06 2000-11-14 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US6458385B2 (en) 1995-03-06 2002-10-01 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5645850A (en) 1995-03-06 1997-07-08 Ethicon, Inc. Blending containing absorbable polyoxaamides
US20010026793A1 (en) 1995-03-06 2001-10-04 Jamiolkowski Dennis D. Hydrogels containing absorbable polyoxaamides
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US6224894B1 (en) 1995-03-06 2001-05-01 Ethicon, Inc. Copolymers of absorbable polyoxaesters
US6372256B2 (en) 1995-03-06 2002-04-16 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5697914A (en) 1995-03-16 1997-12-16 Becton Dickinson And Company Control forward/flashback forward one hand introducer needle and catheter assembly
US6060450A (en) 1995-03-16 2000-05-09 University Of Florida Method for treatment of autoimmune diseases
US5906816A (en) 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5697113A (en) 1995-03-23 1997-12-16 Aminach Bedding & Furniture Manufacturing Ltd. Ventilated infant's mattress
US5542682A (en) 1995-03-27 1996-08-06 American Variseal Slant coil spring and seal
US5736159A (en) 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5972373A (en) 1995-05-02 1999-10-26 Taisho Pharmaceutical Co., Ltd. Taste masking pharmaceutical composition for oral administration
US5939286A (en) 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
WO1996036317A1 (en) 1995-05-18 1996-11-21 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5922253A (en) 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US5882676A (en) 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5718922A (en) 1995-05-31 1998-02-17 Schepens Eye Research Institute, Inc. Intravitreal microsphere drug delivery and method of preparation
WO1996039142A1 (en) 1995-06-06 1996-12-12 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
WO1996040049A1 (en) 1995-06-07 1996-12-19 Alza Corporation Peptide/protein suspended formulations
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
US5972370A (en) 1995-06-07 1999-10-26 Alza Corporation Peptide/protein suspending formulations
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5904935A (en) 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
WO1996040139A1 (en) 1995-06-07 1996-12-19 Alza Corporation Novel formulations for transdermal delivery of pergolide
US5725497A (en) 1995-06-07 1998-03-10 American Cyanamid Company Injection dart system
US5876746A (en) 1995-06-07 1999-03-02 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US20040101557A1 (en) 1995-06-07 2004-05-27 Gibson John W. High viscosity liquid controlled delivery system and medical or surgical device
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5871770A (en) 1995-06-07 1999-02-16 Alza Corporation Implantable system for delivery of fluid-sensitive agents to animals
WO1996040355A1 (en) 1995-06-07 1996-12-19 Cygnus, Inc. Transdermal patch and method for administering 17-deacetyl norgestimate alone or in combination with an estrogen
US5690952A (en) 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US6607529B1 (en) 1995-06-19 2003-08-19 Medtronic Vidamed, Inc. Electrosurgical device
US5782396A (en) 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
US5906830A (en) 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US5814323A (en) 1995-10-16 1998-09-29 Lever Brothers Company, Division Of Conopco, Inc. Cosmetic composition
US6120787A (en) 1995-10-19 2000-09-19 Biogram Ab Sustained release particles
WO1997015296A1 (en) 1995-10-23 1997-05-01 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
WO1997015289A1 (en) 1995-10-25 1997-05-01 Cortecs (Uk) Limited Solubilisation methods
EP0771817A2 (en) 1995-10-30 1997-05-07 Laboratorios S.A.L.V.A.T., S.A. Fatty-acid monoesters of estrogens for the treatment of obesity and/or overweight
US6461605B1 (en) 1995-11-02 2002-10-08 Schering Corporation Continuous low-dose cytokine infusion therapy
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5906599A (en) 1995-11-09 1999-05-25 Intermed, Inc. Device for delivering biological agents
US6190700B1 (en) 1995-12-15 2001-02-20 Takeda Chemical Industries, Ltd. Production of sustained-release preparation for injection
US5851451A (en) 1995-12-15 1998-12-22 Takeda Chemical Industries, Ltd. Production of microspheres
US6592508B1 (en) 1995-12-18 2003-07-15 Integrated Implant Systems, Llc Fiberoptic-guided interstitial seed manual applicator and seed cartridge
US6133249A (en) 1995-12-19 2000-10-17 Macnaught Medical Pty Limited Phospholipid and propylene glycol based lubricant
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US5672549A (en) 1996-01-31 1997-09-30 Sumitomo Bakelite Company Limited Method of producing epoxy resin-encapsulated semiconductor device
US5985305A (en) 1996-02-02 1999-11-16 Alza Corporation Sustained delivery of an active agent using an implantable system
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US20040039376A1 (en) 1996-02-02 2004-02-26 Peery John R. Sustained delivery of an active agent using an implantable system
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US5728396A (en) 1996-02-02 1998-03-17 Alza Corporation Sustained delivery of leuprolide using an implantable system
WO1997028181A2 (en) 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6635268B2 (en) 1996-02-02 2003-10-21 Alza Corporation Sustained delivery of an active agent using an implantable system
US7655257B2 (en) 1996-02-02 2010-02-02 Intarcia Therapeutics, Inc. Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
WO1997031943A1 (en) 1996-03-01 1997-09-04 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JPH09241153A (en) 1996-03-04 1997-09-16 Q P Corp Lipid emulsion for intravenous injection
US6124281A (en) 1996-03-08 2000-09-26 Zeneca Limited Azolobenzazepine derivatives as neurologically active agents
US6069133A (en) 1996-03-14 2000-05-30 The Immune Response Corporation Targeted delivery of genes encoding interferon
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
US6190702B1 (en) 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
US6204022B1 (en) 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
US6074673A (en) 1996-04-22 2000-06-13 Guillen; Manuel Slow-release, self-absorbing, drug delivery system
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US5976109A (en) 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
WO1997041837A2 (en) 1996-05-07 1997-11-13 Alkermes Controlled Therapeutics Inc. Ii Microparticles
US6110503A (en) 1996-05-07 2000-08-29 Alkermes Controlled Therapeutics Inc. Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5916598A (en) 1996-05-07 1999-06-29 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable, biocompatible microparticles containing a biologically active agent
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
WO1997044039A1 (en) 1996-05-20 1997-11-27 Janssen Pharmaceutica N.V. Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
WO1997046204A2 (en) 1996-06-05 1997-12-11 Ashmont Holdings Limited Injectable compositions
US6767887B1 (en) 1996-06-05 2004-07-27 Roche Diagnostics Gmbh Exendin analogues, processes for their preparation and medicaments containing them
WO1997047339A1 (en) 1996-06-14 1997-12-18 Filtertek, S.A. Gravity infusion set for medical infusions
US6258377B1 (en) 1996-07-02 2001-07-10 Provalis Uk Limited Hydrophobic preparations containing medium chain monoglycerides
US6124261A (en) 1996-07-03 2000-09-26 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6235712B1 (en) 1996-07-03 2001-05-22 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998000158A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998000152A1 (en) 1996-07-03 1998-01-08 Alza Corporation Non-aqueous protic peptide formulations
WO1998000157A1 (en) 1996-07-03 1998-01-08 Alza Corporation Aqueous formulations of peptides
WO1998002169A2 (en) 1996-07-15 1998-01-22 Alza Corporation Novel formulations for the administration of fluoxetine
US6218431B1 (en) 1996-07-31 2001-04-17 Bayer Corporation Substituted biphenyls
US7521423B2 (en) 1996-08-08 2009-04-21 Amylin Pharmaceuticals, Inc. Exendin pharmaceutical compositions
US6858576B1 (en) 1996-08-08 2005-02-22 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US20040266692A1 (en) 1996-08-08 2004-12-30 Young Andrew A. Exendin pharmaceutical compositions
US7297761B2 (en) 1996-08-08 2007-11-20 Amylin Pharmaceuticals, Inc. Pharmaceutical compositions containing exendins
US8288338B2 (en) 1996-08-08 2012-10-16 Amylin Pharmaceuticals, Llc Exendin and exendin agonists for eating disorders
US7741269B2 (en) 1996-08-08 2010-06-22 Amylin Pharmaceuticals, Inc. Exendins and exendin agonists for weight reduction and obesity
WO1998007412A1 (en) 1996-08-21 1998-02-26 Alkermes Controlled Therapeutics, Inc. Controlled release microparticles with a hydrophobic material
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998013092A1 (en) 1996-09-27 1998-04-02 American Home Products Corporation Tissue penetration guide
WO1998013091A1 (en) 1996-09-27 1998-04-02 American Home Products Corporation Medical device for the placement of solid materials
US5984890A (en) 1996-09-27 1999-11-16 American Home Products Corporation Medical device for the placement of solid materials
US6074377A (en) 1996-10-10 2000-06-13 Sanfilippo, Ii; Dominic Joseph Method of installing vascular access device
WO1998016250A1 (en) 1996-10-16 1998-04-23 Alza Corporation Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
US6730328B2 (en) 1996-10-16 2004-05-04 Victoria Knepp Maskiewicz Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity
WO1998017315A2 (en) 1996-10-24 1998-04-30 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
US6187095B1 (en) 1996-10-31 2001-02-13 Samsel K. Labrecque Process and apparatus for coating surgical sutures
US5817129A (en) 1996-10-31 1998-10-06 Ethicon, Inc. Process and apparatus for coating surgical sutures
US6191102B1 (en) 1996-11-05 2001-02-20 Eli Lilly And Company Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity
EP0841359A1 (en) 1996-11-06 1998-05-13 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US6177096B1 (en) 1996-11-11 2001-01-23 Lts Lohmann Therapie-Systeme Gmbh Water soluble film for oral administration with instant wettability
US8865202B2 (en) 1996-11-11 2014-10-21 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US6709671B2 (en) 1996-11-11 2004-03-23 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US6592887B2 (en) 1996-11-11 2003-07-15 Lts Lohmann Therapie-Systeme Ag Water soluble film for oral administration with instant wettability
US5948430A (en) 1996-11-11 1999-09-07 Lts Lohmann Therapie-Systeme Gmbh Water soluble film for oral administration with instant wettability
US6284264B1 (en) 1996-11-11 2001-09-04 Lts Lohmann Therapie-Systeme Gmbh Water soluble film for oral administration with instant wettability
US5928666A (en) 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
WO1998020930A1 (en) 1996-11-15 1998-05-22 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US20030044467A1 (en) 1996-12-20 2003-03-06 Brodbeck Kevin J. Gel composition and methods
US6331311B1 (en) 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
WO1998027963A2 (en) 1996-12-20 1998-07-02 Alza Corporation Gel composition and methods
US20060013879A9 (en) 1996-12-20 2006-01-19 Brodbeck Kevin J Gel composition and methods
US6673767B1 (en) 1996-12-20 2004-01-06 Alza Corporation Gel composition and methods
US6468961B1 (en) 1996-12-20 2002-10-22 Alza Corporation Gel composition and methods
WO1998027960A2 (en) 1996-12-20 1998-07-02 Bioglan Ireland (R & D) Limited A nitroimidazole gel composition
US20020034532A1 (en) 1996-12-20 2002-03-21 Brodbeck Kevin J. Injectable depot gel composition and method of preparing the composition
US6130200A (en) 1996-12-20 2000-10-10 Alza Corporation Gel composition and methods
WO1998027962A2 (en) 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
US6956026B2 (en) 1997-01-07 2005-10-18 Amylin Pharmaceuticals, Inc. Use of exendins for the reduction of food intake
US7138375B2 (en) 1997-01-07 2006-11-21 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for lowering plasma lipid
US20020137666A1 (en) 1997-01-07 2002-09-26 Nigel Robert Arnold Beeley Use of exendins and agonists thereof for the reduction of food intake
US7115569B2 (en) 1997-01-07 2006-10-03 Amylin Pharmaceuticals, Inc. Exendins, exendin agonists, and methods for their use
US6989366B2 (en) 1997-01-07 2006-01-24 Amylin Pharmaceuticals, Inc. Exendins, exendin agonists, and methods for their use
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1998032463A2 (en) 1997-01-28 1998-07-30 Pharmacia & Upjohn Company Lyophilizate of lipid complex of water insoluble porphyrins
US5945126A (en) 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US5997527A (en) 1997-03-24 1999-12-07 Alza Corporation Self adjustable exit port
US6217906B1 (en) 1997-03-24 2001-04-17 Alza Corporation Self adjustable exit port
WO1998042317A2 (en) 1997-03-24 1998-10-01 Alza Corporation Implantable delivery device with self adjustable exit port
US5874388A (en) 1997-04-02 1999-02-23 Dow Corning Corporation Lubricant composition for disc brake caliper pin and a disc brake asembly containing the lubricant
US6127520A (en) 1997-04-15 2000-10-03 Regents Of The University Of Michigan Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles
WO1998047487A1 (en) 1997-04-17 1998-10-29 Dumex-Alpharma A/S A novel bioadhesive drug delivery system based on liquid crystals
US6217893B1 (en) 1997-04-18 2001-04-17 Pharma Biotech Sustained-release compositions and method for preparing same
US20040265273A1 (en) 1997-04-28 2004-12-30 Hong Li Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
WO1998051282A1 (en) 1997-05-13 1998-11-19 Imarx Pharmaceutical Corp. Solid porous matrices and methods of making and using the same
US20020004481A1 (en) 1997-06-13 2002-01-10 Jeffrey L. Cleland Controlled release microencapsulated ngf formulation
US6113947A (en) 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
WO1998058698A1 (en) 1997-06-20 1998-12-30 Akzo Nobel N.V. Preloaded implantation device
WO1999003453A1 (en) 1997-07-14 1999-01-28 Lek, Tovarna Farmacevtskih In Kemic^¿Nih Izdelkov , D.D. Novel pharmaceutical formulation with controlled release of active substances
WO1999004659A1 (en) 1997-07-24 1999-02-04 Evgeni Gennadievich Durnev Child bib containing an absorbing substance (material)
US6840931B2 (en) 1997-07-25 2005-01-11 Alza Corporation Osmotic delivery system flow modulator apparatus and method
US20030114837A1 (en) 1997-07-25 2003-06-19 Peterson Lewis L. Osmotic delivery system flow modulator apparatus and method
US6524305B1 (en) 1997-07-25 2003-02-25 Alza Corporation Osmotic delivery system flow modulator apparatus and method
US20050131389A1 (en) 1997-07-25 2005-06-16 Peterson Lewis L. Osmotic delivery system flow modulator apparatus and method
WO1999004767A2 (en) 1997-07-25 1999-02-04 Alza Corporation Osmotic delivery system with semipermeable plug
WO1999004768A2 (en) 1997-07-25 1999-02-04 Alza Corporation Osmotic delivery system flow modulator apparatus
US20010027311A1 (en) 1997-07-25 2001-10-04 Guohua Chen Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6287295B1 (en) 1997-07-25 2001-09-11 Alza Corporation Osmotic delivery system, osmotic delivery system semimpermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6923800B2 (en) 1997-07-25 2005-08-02 Alza Corporation Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
US6478768B1 (en) 1997-08-08 2002-11-12 Gaplast Gmbh Implant syringe
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
WO1999012549A2 (en) 1997-09-09 1999-03-18 West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited Controlled release microsphere delivery system
US6023802A (en) 1997-09-10 2000-02-15 King; Susan Melton Infant sleeper
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999016419A1 (en) 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
US6133429A (en) 1997-10-03 2000-10-17 Becton Dickinson And Company Chromophores useful for the preparation of novel tandem conjugates
USD399821S (en) 1997-11-07 1998-10-20 Motorola, Inc. Front section of a battery charger
WO1999025728A1 (en) 1997-11-14 1999-05-27 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6569420B2 (en) 1997-12-08 2003-05-27 Genentech, Inc. Human interferon-ε: a type I interferon
WO1999029306A1 (en) 1997-12-12 1999-06-17 Biohybrid Technologies, Inc. Devices for cloaking transplanted cells
US20030059471A1 (en) 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US6375978B1 (en) 1997-12-22 2002-04-23 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US20010022974A1 (en) 1997-12-29 2001-09-20 Rupal Ayer Osmotic delivery system with membrane plug retention mechanism
US20040243106A1 (en) 1997-12-29 2004-12-02 Rupal Ayer Osmotic delivery device with membrane plug retention mechanism
US6190350B1 (en) 1997-12-29 2001-02-20 Alza Corporation Implanter device for subcutaneous implants
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6976981B2 (en) 1997-12-29 2005-12-20 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
US6899887B2 (en) 1997-12-29 2005-05-31 Micron Technology, Inc. Osmotic delivery system with membrane plug retention mechanism
US20010021822A1 (en) 1997-12-29 2001-09-13 Rupal Ayer Osmotic delivery system with membrane plug retention mechanism
EP1300173A2 (en) 1997-12-29 2003-04-09 Alza Corporation Implanter device for subcutaneous implants
US6270787B1 (en) 1997-12-29 2001-08-07 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
EP1300129A2 (en) 1997-12-29 2003-04-09 Alza Corporation Implant vial
WO1999033449A1 (en) 1997-12-30 1999-07-08 Alza Corporation Beneficial agent delivery system with membrane plug
US6113938A (en) 1997-12-30 2000-09-05 Alza Corporation Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents
US20040024068A1 (en) 1998-01-23 2004-02-05 Trustees Of Tufts College Antimicrobial compounds
WO1999039700A1 (en) 1998-02-06 1999-08-12 Eurand International S.P.A. Pharmaceutical compositions in form of nanoparticles comprising lipidic substances and amphiphilic substances and related preparation process
US6017545A (en) 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999040788A1 (en) 1998-02-13 1999-08-19 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US7928065B2 (en) 1998-02-13 2011-04-19 Amylin Pharmaceuticals, Inc. Methods of treatment using exendin peptides or GLP-1 peptides
US6402716B1 (en) 1998-02-20 2002-06-11 Lg Chemical Ltd. Syringe assembly
USD408917S (en) 1998-02-26 1999-04-27 Minnesota Mining And Manufacturing Company Membrane support structure of a flow through cell for blood gas measurement
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6183461B1 (en) 1998-03-11 2001-02-06 Situs Corporation Method for delivering a medication
US20020136848A1 (en) 1998-03-12 2002-09-26 Fumio Yoshii Lactone-containing resin composition, molded object thereof, and film
US6029361A (en) 1998-03-25 2000-02-29 Ultratech Stepper, Inc. Air-guage nozzle probe structure for microlithographic image focusing
US6074660A (en) 1998-04-20 2000-06-13 Ethicon, Inc. Absorbable polyoxaesters containing amines and/ or amido groups
EP1084703A1 (en) 1998-05-29 2001-03-21 Sumitomo Pharmaceuticals Company, Limited Controlled release preparations having multi-layer structure
WO1999062501A1 (en) 1998-05-29 1999-12-09 Sumitomo Pharmaceuticals Company, Limited Controlled release preparations having multi-layer structure
US7101567B1 (en) 1998-05-29 2006-09-05 Dainippon Sumitomo Pharma Co., Ltd. Controlled release preparations having multi-layer structure
US20140121741A1 (en) 1998-06-03 2014-05-01 Spr Therapeutics, Llc Systems and methods to place one or more leads in muscle for providing electrical stimulation to treat pain
WO1999064061A1 (en) 1998-06-12 1999-12-16 Bionebraska, Inc. GLUCAGON-LIKE PEPTIDE-1 IMPROVES β-CELL RESPONSE TO GLUCOSE IN SUBJECTS WITH IMPAIRED GLUCOSE TOLERANCE
US6277413B1 (en) 1998-07-17 2001-08-21 Skyepharma, Inc. Biodegradable compositions for the controlled release of encapsulated substances
US20040225113A1 (en) 1998-07-21 2004-11-11 Lafleur David W. Keratinocyte derived interferon
US6472512B1 (en) 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6270700B1 (en) 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides
US20080065090A1 (en) 1998-08-14 2008-03-13 Scribner Robert M Methods and apparatus for placing materials into bone
USD415073S (en) 1998-08-17 1999-10-12 ScooterBug, Inc. Stroller
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6551613B1 (en) 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
WO2000013663A1 (en) 1998-09-09 2000-03-16 Alza Corporation Dosage form comprising liquid formulation
US5951521A (en) 1998-09-25 1999-09-14 Minimed Inc. Subcutaneous implantable sensor set having the capability to remove deliver fluids to an insertion site
US6645192B2 (en) 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
US6447522B2 (en) 1998-09-30 2002-09-10 C. R. Bard, Inc. Implant delivery system
US20040047888A1 (en) 1998-09-30 2004-03-11 Kenison Dale C. Pellet implant system for immediate and delayed release of antiparasitic drug
US6248112B1 (en) 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6053927A (en) 1998-10-15 2000-04-25 Rsh-Gs Trust Apparatus and method for implant removal
US6544239B2 (en) 1998-10-16 2003-04-08 Bio-Plexus Delaware, Inc. Releasable locking needle assembly with optional release accessory therefor
US20020048600A1 (en) 1998-11-02 2002-04-25 Padmanabh Bhatt Controlled delivery of active agents
US20040157951A1 (en) 1998-11-13 2004-08-12 Wolf David E. Monodisperse preparations useful with implanted devices
WO2000029206A1 (en) 1998-11-13 2000-05-25 Sensor Technologies Inc. Monodisperse preparations useful with implanted devices
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6903186B1 (en) 1998-12-07 2005-06-07 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S Analogues of GLP-1
US20010036472A1 (en) 1998-12-17 2001-11-01 Wong Patrick S.-L. Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US6419952B2 (en) 1998-12-17 2002-07-16 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
WO2000038652A1 (en) 1998-12-23 2000-07-06 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
US6997922B2 (en) 1998-12-31 2006-02-14 Alza Corporation Osmotic delivery system having space efficient piston
US6544252B1 (en) 1998-12-31 2003-04-08 Alza Corporation Osmotic delivery system having space efficient piston
WO2000039280A2 (en) 1998-12-31 2000-07-06 Viragen, Inc. Leukocyte-derived interferon preparations
WO2000040273A2 (en) 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
US6703225B1 (en) 1999-01-12 2004-03-09 Sumitomo Pharmaceuticals Company, Limited Interferon-α
US6433144B1 (en) 1999-01-12 2002-08-13 Viragen, Inc. Compositions of highly-purified natural mixtures of type I Interferon derived from leukocytes and methods
US7153825B2 (en) 1999-01-14 2006-12-26 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression using modified exendins
US20090215694A1 (en) 1999-01-14 2009-08-27 Amylin Pharmaceuticals, Inc Lyophilized Formulations of Exendins and Exendin Agonist Analogs
US6872700B1 (en) 1999-01-14 2005-03-29 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US20060069029A1 (en) 1999-01-14 2006-03-30 Kolterman Orville G Exendin analog formulations
US6902744B1 (en) 1999-01-14 2005-06-07 Amylin Pharmaceuticals, Inc. Exendin agonist formulations and methods of administration thereof
WO2000041548A2 (en) 1999-01-14 2000-07-20 Amylin Pharmaceuticals, Inc. Methods for glucagon suppression
US8048438B2 (en) 1999-02-08 2011-11-01 Intarcia Therapeutics, Inc. Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8992961B2 (en) 1999-02-08 2015-03-31 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20080226625A1 (en) 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non- aqueous single phase viscous vehicles and formulations utlizing such vehicles
US20150231256A1 (en) 1999-02-08 2015-08-20 Intarcia Therapeutics Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20170119855A1 (en) 1999-02-08 2017-05-04 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20170319662A1 (en) 1999-02-08 2017-11-09 Intarcia Therapeutics Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20080226689A1 (en) 1999-02-08 2008-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8372424B2 (en) 1999-02-08 2013-02-12 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030108609A1 (en) 1999-02-08 2003-06-12 Berry Stephen A. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
WO2000045790A2 (en) 1999-02-08 2000-08-10 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US8268341B2 (en) 1999-02-08 2012-09-18 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20110160708A1 (en) 1999-02-08 2011-06-30 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles
US8173150B2 (en) 1999-02-08 2012-05-08 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles
US6451974B1 (en) 1999-03-17 2002-09-17 Novo Nordisk A/S Method of acylating peptides and novel acylating agents
US6835194B2 (en) 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
WO2000054745A2 (en) 1999-03-18 2000-09-21 Durect Corporation Devices and methods for pain management
WO2000059476A1 (en) 1999-04-05 2000-10-12 Pharmaceutical Discovery Corporation Methods for fine powder formation
US6670368B1 (en) 1999-04-06 2003-12-30 Astrazeneca Ab Pyrimidine compounds with pharmaceutical activity
EP1046399A1 (en) 1999-04-19 2000-10-25 Schering Corporation HCV combination therapy, containing ribavirin in association with antioxidants
WO2000066138A2 (en) 1999-04-30 2000-11-09 Bionebraska, Inc. Metabolic intervention with glp-1 to improve the function of ischemic and reperfused tissue
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
WO2000066087A2 (en) 1999-05-03 2000-11-09 Southern Biosystems, Inc. Emulsion-based processes for making microparticles
WO2000067728A2 (en) 1999-05-07 2000-11-16 Pharmasol Gmbh Lipid particles on the basis of mixtures of liquid and solid lipids and method for producing same
USD430671S (en) 1999-05-10 2000-09-05 Shute Wallace B Obstetrical forceps
US6428517B1 (en) 1999-05-10 2002-08-06 Milestone Scientific, Inc. Hand-piece for injection device with a retractable and rotating needle
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6593295B2 (en) 1999-05-17 2003-07-15 Conjuchem, Inc. Long lasting insulinotropic peptides
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6146139A (en) 1999-06-01 2000-11-14 Harrison, Iii; Louis V. Forceps apparatus
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US20060233841A1 (en) 1999-06-04 2006-10-19 Brodbeck Kevin J Implantable gel compositions and method of manufacture
US6485706B1 (en) 1999-06-04 2002-11-26 Delrx Pharmaceutical Corp. Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same
US20030059376A1 (en) 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US20010040326A1 (en) 1999-06-14 2001-11-15 Lord Corporation Resilient member with deformed element and method of forming same
US6833256B1 (en) 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US7766924B1 (en) 1999-07-28 2010-08-03 Cardica, Inc. System for performing anastomosis
USD445975S1 (en) 1999-08-27 2001-07-31 Black & Decker, Inc. Base unit for a hand held vacuum cleaner
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
WO2001019345A1 (en) 1999-09-10 2001-03-22 Astrazeneca Ab Method to obtain microparticles
US6887849B2 (en) 1999-10-15 2005-05-03 Conjuchem, Inc. Long lasting synthetic glucagon-like peptide {GLP-1}
US6821949B2 (en) 1999-10-15 2004-11-23 Conjuchem, Inc. Long lasting synthetic glucagon-like peptide (GLP-1)
WO2001028631A1 (en) 1999-10-15 2001-04-26 Deschutes Medical Products, Inc. Brachytherapy instrument and methods
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6752753B1 (en) 1999-10-15 2004-06-22 Deschutes Medical Products, Inc. Brachytherapy instrument and methods
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
WO2001028525A2 (en) 1999-10-21 2001-04-26 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001043528A2 (en) 1999-12-17 2001-06-21 Durect Corporation Devices and methods in intracerebrospinal delivery of morphine-6-glucuronide
US6508808B1 (en) 1999-12-21 2003-01-21 Alza Corporation Valve for osmotic devices
US6682522B2 (en) 1999-12-21 2004-01-27 Alza Corporation Valve for osmotic devices
US20010031790A1 (en) 1999-12-22 2001-10-18 Beisswenger Paul J. Treatment for complications of type 2 diabetes
US6283949B1 (en) 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
WO2001051041A1 (en) 2000-01-13 2001-07-19 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US20020012818A1 (en) 2000-01-19 2002-01-31 Sakari Ruppi Coated body with nanocrystalline CVD coating for enhanced edge toughness and reduced friction
US20030186858A1 (en) 2000-01-31 2003-10-02 Arentsen Anne Charlotte Crystallisation of a GLP-1 analogue
US20030138491A1 (en) 2000-02-10 2003-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US20030032947A1 (en) 2000-02-15 2003-02-13 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
WO2001068168A1 (en) 2000-03-13 2001-09-20 Leiras Oy Device for inserting implants
US20030040699A1 (en) 2000-03-13 2003-02-27 Christine Talling Device for inserting implants
US6579851B2 (en) 2000-03-14 2003-06-17 Amylin Pharmaceuticals, Inc. Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility
US20030211974A1 (en) 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US20010031940A1 (en) 2000-03-23 2001-10-18 Hans-Joachim Loos Device for administering implants
US20020098180A1 (en) 2000-03-24 2002-07-25 Huan-Yao Lei Fullerene pharmaceutical compositions for preventing or treating disorders
US9044209B2 (en) 2000-04-14 2015-06-02 Attenuex Technologies, Inc. Method of removing an inflated implant
WO2001078683A2 (en) 2000-04-19 2001-10-25 Genentech, Inc. Sustained release formulations comprising growth hormone
US20020001631A1 (en) 2000-04-19 2002-01-03 Franklin Okumu Sustained release formulations
US6992065B2 (en) 2000-04-19 2006-01-31 Genentech, Inc. Sustained release formulations
US6875748B2 (en) 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
US6589157B2 (en) 2000-05-18 2003-07-08 Integrated Implant Systems, L.L.C. Drive mechanism for medical instrument
US6706689B2 (en) 2000-05-19 2004-03-16 Amylin Pharmaceuticals, Inc. Treatment of acute coronary syndrome with GLP-1
US20030113380A1 (en) 2000-05-25 2003-06-19 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6667061B2 (en) 2000-05-25 2003-12-23 Alkermes Controlled Therapeutics, Inc. Preparation of injectable suspensions having improved injectability
US7084243B2 (en) 2000-06-16 2006-08-01 Eli Lilly And Company Glucagon-like peptide-1 analogs
US20020037309A1 (en) 2000-08-10 2002-03-28 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
US6547250B1 (en) 2000-08-21 2003-04-15 Westport Research Inc. Seal assembly with two sealing mechanisms for providing static and dynamic sealing
US8454552B2 (en) 2000-08-24 2013-06-04 Cardiac Science Corporation Method for constructing an instrument with a covered bore for subcutaneous implantation
US20100331868A1 (en) 2000-08-24 2010-12-30 Bardy Gust H Method For Constructing An Instrument With A Two-Part Plunger For Subcutaneous Implantation
US8251946B2 (en) 2000-08-24 2012-08-28 Cardiac Science, Inc. Method for constructing an instrument with a two-part plunger for subcutaneous implantation
US20040115236A1 (en) 2000-10-06 2004-06-17 Chan Tai Wah Devices and methods for management of inflammation
WO2002028366A2 (en) 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
US7727519B2 (en) 2000-11-03 2010-06-01 Intarcia Therapeutics, Inc. Method for treating hepatitis C virus with omega interferon
US20050201980A1 (en) 2000-11-03 2005-09-15 Moran Stanford M. Method for short-term and long-term drug dosimetry
US20020197235A1 (en) 2000-11-03 2002-12-26 Moran Stanford Mark Method for short-term and long-term drug dosimetry
WO2002036072A2 (en) 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry
WO2002067895A2 (en) 2000-11-16 2002-09-06 Durect Corporation Implant dosage form and use thereof for the delivery of a cholesterol lowering agent
US6626863B1 (en) 2000-11-22 2003-09-30 Nusaf, L.L.C. Safety syringe
WO2002043800A2 (en) 2000-11-29 2002-06-06 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
US20050070883A1 (en) 2000-11-29 2005-03-31 Brown James E Devices and methods for controlled delivery from a drug delivery device
WO2002045752A2 (en) 2000-12-08 2002-06-13 Leo Pharma A/S Dermal anti-inflammatory composition
US7199217B2 (en) 2000-12-13 2007-04-03 Eli Lilly And Company Amidated glucagon-like peptide-1
WO2002047716A2 (en) 2000-12-13 2002-06-20 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US20030078616A1 (en) 2000-12-14 2003-04-24 Core Medical, Inc. Plug with detachable guidewire element and methods for use
US20020141985A1 (en) 2000-12-14 2002-10-03 Amylin Parmaceuticals, Inc. Peptide YY and peptide YY agonists for treatment of metabolic disorders
US8273713B2 (en) 2000-12-14 2012-09-25 Amylin Pharmaceuticals, Llc Methods of treating obesity using PYY[3-36]
US20020077599A1 (en) 2000-12-19 2002-06-20 Animas Corporation Transcutaneous inserter for low-profile infusion sets
US6899898B2 (en) 2000-12-21 2005-05-31 Nektar Therapeutics Induced phase transition method for the production of microparticles containing hydrophobic active agents
USD472896S1 (en) 2000-12-23 2003-04-08 Andreas Peiker Telephone support
WO2002069983A1 (en) 2001-03-01 2002-09-12 Bharat Serums & Vaccines Ltd. Amphotericin b aqueous composition
WO2002076344A1 (en) 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
WO2002083216A1 (en) 2001-04-13 2002-10-24 Becton Dickinson And Company Method of intradermally injecting substances
WO2002085428A2 (en) 2001-04-19 2002-10-31 Microsolutions, Inc. Implantable osmotic pump
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US6514517B2 (en) 2001-06-20 2003-02-04 Ethicon, Inc. Antimicrobial coatings for medical devices
US20020197185A1 (en) 2001-06-20 2002-12-26 Jamiolkowski Dennis D. Antimicrobial coatings for medical devices
US20030045454A1 (en) 2001-06-21 2003-03-06 Franklin Okumu Sustained release formulation
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
US7163697B2 (en) 2001-06-22 2007-01-16 Johns Hopkins University School Of Medicine Biodegradable polymer compositions, compositions and uses related thereto
US20030104063A1 (en) 2001-06-22 2003-06-05 Babcock Walter C. Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers
US20030007992A1 (en) 2001-06-22 2003-01-09 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
WO2003000230A1 (en) 2001-06-22 2003-01-03 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030138403A1 (en) 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
WO2003007981A1 (en) 2001-07-20 2003-01-30 Intermune, Inc. Methods of treating liver fibrosis
WO2003011892A2 (en) 2001-07-31 2003-02-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1 exendin-4 peptide analogs and uses thereof
US7101843B2 (en) 2001-08-23 2006-09-05 Eli Lilly And Company Glucagon-like peptide-1 analogs
US20040198654A1 (en) 2001-08-23 2004-10-07 Wolfgang Glaesner Glucagon-like peptide-1analogs
US20030118660A1 (en) 2001-08-31 2003-06-26 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
WO2003020245A1 (en) 2001-08-31 2003-03-13 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US7666835B2 (en) 2001-09-07 2010-02-23 Imperial Innovations Limited Oxyntomodulin for preventing or treating excess weight
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
US20060224145A1 (en) 2001-09-17 2006-10-05 Gillis Edward M Device and method for accurate delivery of an active agent
WO2003024503A2 (en) 2001-09-17 2003-03-27 Durect Corporation Device and method for accurate delivery of an active agent
US8217001B2 (en) 2001-09-24 2012-07-10 Imperial Innovations Limited Modification of feeding behavior
US7459432B2 (en) 2001-09-24 2008-12-02 Imperial College Innovations Ltd. Modification of feeding behavior
US7041646B2 (en) 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
WO2003030923A1 (en) 2001-10-05 2003-04-17 Intermune, Inc. Method of treating hepatitis virus infection with a multiphasic interferon delivery profile
US20040002442A1 (en) 2001-10-05 2004-01-01 Clark Pan Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
US20030078618A1 (en) 2001-10-19 2003-04-24 Fey Kate E. System and method for removing implanted devices
US20030097121A1 (en) 2001-10-24 2003-05-22 Claude Jolly Implantable fluid delivery apparatuses and implantable electrode
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20070248572A1 (en) 2001-11-09 2007-10-25 Intarica Therapeutics, Inc. Method for treating diseases with omega interferon
US20030157178A1 (en) 2001-11-14 2003-08-21 Guohua Chen Injectable depot composition
US20030170289A1 (en) 2001-11-14 2003-09-11 Guohua Chen Injectable depot compositions and uses thereof
WO2003041684A2 (en) 2001-11-14 2003-05-22 Alza Corporation Injectable depot compositions and uses thereof
US20030180364A1 (en) 2001-11-14 2003-09-25 Guohua Chen Catheter injectable depot compositions and uses thereof
US7829109B2 (en) 2001-11-14 2010-11-09 Durect Corporation Catheter injectable depot compositions and uses thereof
WO2003041757A2 (en) 2001-11-14 2003-05-22 Alza Corporation Catheter injectable depot compositions and uses thereof
US20030191099A1 (en) 2001-11-27 2003-10-09 Schering Ag 17alpha-alkyl-17beta-oxy-estratrienes and intermediate products for their production, use of the 17alpha-alkyl-17beta-oxy-estratrienes for the production of pharmaceutical agents as well as pharmaceutical preparations
US20030108608A1 (en) 2001-12-12 2003-06-12 Erik Laridon Thermoplastic articles comprising silver-containing antimicrobials and high amounts of carboxylic acid salts for increased surface-available silver
US20030135153A1 (en) 2001-12-17 2003-07-17 Charles Hagemeier Drug implant injection device
EP1323450A1 (en) 2001-12-18 2003-07-02 Risdon Pharma GmbH Syringe device
WO2003053400A1 (en) 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
US7141547B2 (en) 2001-12-21 2006-11-28 Human Genome Sciences, Inc. Albumin fusion proteins comprising GLP-1 polypeptides
US8058233B2 (en) 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
US20040029784A1 (en) 2002-01-22 2004-02-12 Hathaway David R. Methods and compositions for treating polycystic ovary syndrome
WO2003066585A2 (en) 2002-02-08 2003-08-14 Alkermes Controlled Therapeutics, Inc. Polymer-based compositions for sustained release
US8257682B2 (en) 2002-02-27 2012-09-04 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7589169B2 (en) 2002-02-27 2009-09-15 Pharmain Corporation Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US8277776B2 (en) 2002-02-27 2012-10-02 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US7790140B2 (en) 2002-02-27 2010-09-07 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US8231859B2 (en) 2002-02-27 2012-07-31 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003072133A2 (en) 2002-02-28 2003-09-04 Norferm Da Immunostimulatory agent comprising a biomass of methanotrophic bacterium
WO2003072113A1 (en) 2002-02-28 2003-09-04 Norbrook Laboratories Limited Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US20050118221A1 (en) 2002-02-28 2005-06-02 William Blakely Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound
US20030215515A1 (en) 2002-04-11 2003-11-20 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
US6960192B1 (en) 2002-04-23 2005-11-01 Insulet Corporation Transcutaneous fluid delivery system
US20030220617A1 (en) 2002-05-22 2003-11-27 C. Dickerson Co. Safety needle introducer and universal needle protector for vascular access devices
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20140163057A1 (en) 2002-05-31 2014-06-12 Titan Pharmaceuticals, Inc. Implantable Polymeric Device for Sustained Release of Buprenorphine
US7074423B2 (en) 2002-06-17 2006-07-11 Alza Corporation Osmotic delivery system with early zero order push power engine
US20030233101A1 (en) 2002-06-17 2003-12-18 Senorx, Inc. Plugged tip delivery tube for marker placement
US20040097906A1 (en) 2002-06-17 2004-05-20 Fereira Pamela J. Osmotic delivery system with early zero order push power engine
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US7112335B2 (en) 2002-06-26 2006-09-26 Alza Corporation Minimally compliant, volume-efficient piston for osmotic drug delivery systems
US6939556B2 (en) 2002-06-26 2005-09-06 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
WO2004002565A1 (en) 2002-06-26 2004-01-08 Alza Corporation Minimally compliant, volume efficient piston for osmotic drug delivery systems
US20060014678A1 (en) 2002-06-28 2006-01-19 Imperial College Innovations Ltd. Modification of feeding behavior
US20040001689A1 (en) 2002-06-28 2004-01-01 Intel Corporation System and method for improving audio during post-production of video recordings
US20040022859A1 (en) 2002-07-31 2004-02-05 Guohua Chen Injectable multimodal polymer depot compositions and uses thereof
US20040024069A1 (en) 2002-07-31 2004-02-05 Guohua Chen Injectable depot compositions and uses thereof
US20060084922A1 (en) 2002-09-04 2006-04-20 Ruark Botha Device for securing a blood vessel cannula to a body
WO2004026106A2 (en) 2002-09-18 2004-04-01 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US20040215133A1 (en) 2002-09-18 2004-10-28 Allergan, Inc. Apparatus for delivery of ocular implants
WO2004035762A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
WO2004034975A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Sustained release profile modification
WO2004036186A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
WO2004035754A2 (en) 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20040209801A1 (en) 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040151753A1 (en) 2002-11-06 2004-08-05 Guohua Chen Controlled release depot formulations
US20050009742A1 (en) 2002-11-20 2005-01-13 Goran Bertilsson Compounds and methods for increasing neurogenesis
US6969702B2 (en) 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
US20040102762A1 (en) 2002-11-21 2004-05-27 Gilbert Scott Jay Osmotic delivery device having a two-way valve and dynamically self-adjusting flow channel
US7316680B2 (en) 2002-11-21 2008-01-08 Intarcia Therapeutics, Inc. Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
WO2004052336A2 (en) 2002-12-10 2004-06-24 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20040266683A1 (en) 2002-12-17 2004-12-30 Hathaway David R Prevention and treatment of cardiac arrhythmias
WO2004056338A2 (en) 2002-12-19 2004-07-08 Alza Corporation Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US20040224903A1 (en) 2002-12-19 2004-11-11 Stephen Berry Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US8398967B2 (en) 2002-12-19 2013-03-19 Intarcia Therapeutics, Inc. Particle formulations for use in pharmaceutical compositions
US20090087408A1 (en) 2002-12-19 2009-04-02 Intarcia Therapeutics, Inc. Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
US20080064636A1 (en) 2003-01-10 2008-03-13 Imperial College Innovations Limited Modification of Feeding Behaviour
US7825091B2 (en) 2003-01-10 2010-11-02 Imperial Innovations Limited Modification of feeding behaviour
US20040142867A1 (en) 2003-01-14 2004-07-22 Kiyomoto Oi Stabilized proteinic preparation
US20070149011A1 (en) 2003-02-18 2007-06-28 Medconx, Inc. Male medical device electrical connector with engineered friction fit
US20050276856A1 (en) 2003-03-31 2005-12-15 Fereira Pamela J Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20050010196A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
WO2004089335A2 (en) 2003-03-31 2004-10-21 Alza Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
US7207982B2 (en) 2003-03-31 2007-04-24 Alza Corporation Osmotic pump with means for dissipating internal pressure
US20050008661A1 (en) 2003-03-31 2005-01-13 Fereira Pamela J. Non-aqueous single phase vehicles and formulations utilizing such vehicles
US20040199140A1 (en) 2003-04-03 2004-10-07 Rue Matthew L. Implanting device and method of using same
USD492995S1 (en) * 2003-04-03 2004-07-13 Valera Pharmaceuticals, Inc. Implanting device
WO2004089458A1 (en) 2003-04-03 2004-10-21 Valera Pharmaceuticals, Inc. Implanting device and method of using same
US7214206B2 (en) 2003-04-03 2007-05-08 Valera Pharmaceuticals, Inc. Implanting device and method of using same
US20050079200A1 (en) 2003-05-16 2005-04-14 Jorg Rathenow Biocompatibly coated medical implants
WO2004103342A2 (en) 2003-05-16 2004-12-02 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
US20050215475A1 (en) 2003-05-30 2005-09-29 John Ong Transmucosal delivery of peptides and proteins
US20050079202A1 (en) 2003-05-30 2005-04-14 Guohua Chen Implantable elastomeric depot compositions and uses thereof
US20060178304A1 (en) 2003-06-03 2006-08-10 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
US20050004557A1 (en) 2003-06-12 2005-01-06 Russell Scott M. Orifice device having multiple channels with varying flow rates for drug delivery
US20050010942A1 (en) 2003-07-09 2005-01-13 Samsung Electronics Co., Ltd. Optical disc drive
US20080260838A1 (en) 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US7205409B2 (en) 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
US7241457B2 (en) 2003-09-30 2007-07-10 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
US20050070927A1 (en) 2003-09-30 2005-03-31 Feinberg Marc E. Tissue approximation device
US20050095284A1 (en) 2003-10-31 2005-05-05 Alza Corporation Osmotic pump with self-retaining, fast-start membrane plug
US7407499B2 (en) 2003-10-31 2008-08-05 Intarcia Therapeutics, Inc. Osmotic pump with self-retaining, fast-start membrane plug
US20050101943A1 (en) 2003-11-06 2005-05-12 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20050118206A1 (en) 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
WO2005048930A2 (en) 2003-11-14 2005-06-02 Alza Corporation Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050112188A1 (en) 2003-11-17 2005-05-26 Eliaz Rom E. Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
WO2005048952A2 (en) 2003-11-17 2005-06-02 Alza Corporation Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
US20170319470A1 (en) 2003-11-17 2017-11-09 Intarcia Therapeutics, Inc. Methods of manufacturing viscous liquid pharmaceutical formulations
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20130052237A1 (en) 2003-11-17 2013-02-28 Intarcia Therapeutics, Inc. Methods of Manufacturing Viscous Liquid Pharmaceutical Formulations
US7964183B2 (en) 2003-11-17 2011-06-21 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US8257691B2 (en) 2003-11-17 2012-09-04 Intarcia Therapeutics, Inc. Composition and dosage form comprising a particle formulation and suspending vehicle
US20050131386A1 (en) 2003-12-15 2005-06-16 Freeman Lynetta J. Method and device for minimally invasive implantation of biomaterial
US20050143749A1 (en) 2003-12-31 2005-06-30 Depuy Spine, Inc. Inserter instrument and implant clip
US20050216087A1 (en) 2004-01-05 2005-09-29 St. Francis Medical Technologies, Inc. Disk repair structures for positioning disk repair material
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20060293232A1 (en) 2004-02-11 2006-12-28 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
US8722037B2 (en) 2004-03-19 2014-05-13 Meck Sharp & Dohme B.V. X-ray visible drug delivery device
US20070141102A1 (en) 2004-03-24 2007-06-21 N.V. Organon Drug delivery system based on polyethylene vinylacetate copolymers
US20070166352A1 (en) 2004-04-15 2007-07-19 Alkermes, Inc. Polymer-based sustained release device
US20090247463A1 (en) 2004-04-15 2009-10-01 Alkermes, Inc. Polymer-based sustained release device
US7612176B2 (en) 2004-04-15 2009-11-03 Alkermes, Inc. Polymer-based sustained release device
WO2005102293A1 (en) 2004-04-15 2005-11-03 Amylin Pharmaceuticals, Inc. Poly (lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
US20050271702A1 (en) 2004-04-15 2005-12-08 Wright Steven G Polymer-based sustained release device
WO2005110425A1 (en) 2004-04-15 2005-11-24 Alkermes, Inc. Polymer-based sustained release device
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7563871B2 (en) 2004-04-15 2009-07-21 Alkermes, Inc. Polymer-based sustained release device
EP2133073A1 (en) 2004-04-15 2009-12-16 Amylin Pharmaceuticals, Inc. Poly(lactide-co-glycolide)-based sustained release microcapsules comprising a polypeptide and a sugar
US20080112994A1 (en) 2004-05-25 2008-05-15 Intarcia Therapeutics, Inc. Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
EP1600187A2 (en) 2004-05-27 2005-11-30 Cordis Corporation Orifice device having multiple channels with varying flow rates for drug delivery
US20090042781A1 (en) 2004-06-28 2009-02-12 Novo Nordisk A/S Methods for Treating Diabetes
US20060030526A1 (en) 2004-08-05 2006-02-09 Kui Liu Stable suspension formulations of erythropoietin receptor agonists
WO2006017772A1 (en) 2004-08-05 2006-02-16 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20080110515A1 (en) 2004-08-18 2008-05-15 Waters Investments Limited Defined Lead Path For High Pressure Seal
WO2006023526A2 (en) 2004-08-18 2006-03-02 Waters Investments Limited Defined leak path for high pressure seal
US20090163447A1 (en) 2004-08-25 2009-06-25 Maggio Edward T Compositions for Drug Administration
US20060094693A1 (en) 2004-09-21 2006-05-04 Point Therapeutics, Inc. Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060073182A1 (en) 2004-10-01 2006-04-06 Wong Vernon G Conveniently implantable sustained release drug compositions
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
US20060084604A1 (en) 2004-10-19 2006-04-20 Chieko Kitaura Transepithelial delivery of peptides with incretin hormone activities
US7604647B2 (en) 2004-10-22 2009-10-20 Medical Instrument Development Laboratories, Inc. Ophthalmic cannula insertion tool and method
US20080207512A1 (en) 2004-11-01 2008-08-28 Amylin Pharmaceuticals, Inc. Methods for Treating Obesity and Obesity Related and Disorders
US20090156474A1 (en) 2004-11-01 2009-06-18 Amylin Pharmaceuticals, Inc. Methods for treating obesity and obesity related diseases and disorders
US20060106399A1 (en) 2004-11-18 2006-05-18 Taras John S Drill guide tissue protector
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060141040A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060160736A1 (en) 2004-12-30 2006-07-20 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
US7393827B2 (en) 2004-12-30 2008-07-01 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring β-cell mass and function
USD608447S1 (en) 2005-01-14 2010-01-19 Edwards Lifesciences Corporation Sensor case
WO2006077250A1 (en) 2005-01-24 2006-07-27 N.V. Organon Applicator for inserting an implant
WO2006077242A1 (en) 2005-01-24 2006-07-27 N.V. Organon Applicator for inserting an implant
US8888745B2 (en) 2005-01-24 2014-11-18 Merck Sharp & Dohme B.V. Applicator for inserting an implant
US20100298807A1 (en) 2005-01-24 2010-11-25 Akzo Nobel N.V. Applicator for inserting an implant
WO2006081279A2 (en) 2005-01-25 2006-08-03 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US8273365B2 (en) 2005-02-03 2012-09-25 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20150231062A1 (en) 2005-02-03 2015-08-20 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8470353B2 (en) 2005-02-03 2013-06-25 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8158150B2 (en) 2005-02-03 2012-04-17 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8114437B2 (en) 2005-02-03 2012-02-14 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US8440226B2 (en) 2005-02-03 2013-05-14 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
TW200634060A (en) 2005-02-03 2006-10-01 Alza Corp Solvent/polymer solutions as suspension vehicles
US8206745B2 (en) 2005-02-03 2012-06-26 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US8211467B2 (en) 2005-02-03 2012-07-03 Intarcia Therapeutics, Inc. Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
US20170348392A1 (en) 2005-02-03 2017-12-07 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US20060193918A1 (en) 2005-02-03 2006-08-31 Rohloff Catherine M Solvent/polymer solutions as suspension vehicles
US7655254B2 (en) 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20060251618A1 (en) 2005-02-03 2006-11-09 Paula Dennis Implantable device for continuous delivery of interferon
US20170181964A1 (en) 2005-02-03 2017-06-29 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US20130034210A1 (en) 2005-02-03 2013-02-07 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US8367095B2 (en) 2005-02-03 2013-02-05 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8299025B2 (en) 2005-02-03 2012-10-30 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2006084139A2 (en) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc. An implantable interferon-containing device
US20110264077A1 (en) 2005-02-03 2011-10-27 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US8940316B2 (en) 2005-02-03 2015-01-27 Intarcia Therapeutics, Inc. Osmotic delivery comprising an insulinotropic peptide and uses thereof
US8992962B2 (en) 2005-02-03 2015-03-31 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9682127B2 (en) 2005-02-03 2017-06-20 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US20060263433A1 (en) 2005-02-03 2006-11-23 Ayer Rupal A Suspension formulation of interferon
US20170368145A1 (en) 2005-02-03 2017-12-28 Intarcia Therapeutics, Inc. Osmotic delivery device comprising an insulinotropic peptide and uses thereof
US20170056476A1 (en) 2005-02-03 2017-03-02 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US9539200B2 (en) 2005-02-03 2017-01-10 Intarcia Therapeutics Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US9095553B2 (en) 2005-02-03 2015-08-04 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US20100297209A1 (en) 2005-02-03 2010-11-25 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US8460694B2 (en) 2005-02-03 2013-06-11 Intarcia Therapeutics, Inc. Solvent/polymer solutions as suspension vehicles
US9526763B2 (en) 2005-02-03 2016-12-27 Intarcia Therapeutics Inc. Solvent/polymer solutions as suspension vehicles
US20070281024A1 (en) 2005-02-03 2007-12-06 Alza Corporation Two-Piece, Internal-Channel Osmotic Delivery System Flow Modulator
US20110104111A1 (en) 2005-02-03 2011-05-05 Intarcia Therapeutics, Inc. Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles
US20080260840A1 (en) 2005-02-03 2008-10-23 Alessi Thomas R Suspension formulations of insulinotropic peptides and uses thereof
WO2006086727A2 (en) 2005-02-09 2006-08-17 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
US20090036364A1 (en) 2005-02-11 2009-02-05 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US20080312157A1 (en) 2005-02-11 2008-12-18 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties
US8202836B2 (en) 2005-03-09 2012-06-19 Imperial Innovations Limited Modified PYY (3-36) peptides and their effects on feeding behavior
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US8114430B2 (en) 2005-03-15 2012-02-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
WO2006101815A2 (en) 2005-03-15 2006-09-28 Alza Corporation Pharmaceutical compositions comprising polyoxaester and active agents for use with osmotic delivery systems
US20060246138A1 (en) 2005-03-15 2006-11-02 Rohloff Catherine M Polyoxaester suspending vehicles for use with implantable delivery systems
US8278267B2 (en) 2005-03-31 2012-10-02 Amylin Pharmaceuticals, Llc Method of modifying food preference comprising administering amylin or amylin agonist
US7879794B2 (en) 2005-03-31 2011-02-01 Amylin Pharmaceuticals, Inc. Methods for controlling binge eating disorders
US20080200383A1 (en) 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
WO2006111169A1 (en) 2005-04-21 2006-10-26 Gastrotech Pharma A/S Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
US20060264890A1 (en) 2005-05-06 2006-11-23 Medtronic Minimed, Inc. Needle inserter and method for infusion device
WO2006131730A1 (en) 2005-06-06 2006-12-14 Camurus Ab Glp-1 analogue formulations
US20060280795A1 (en) 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
US20080269725A1 (en) 2005-07-22 2008-10-30 Trent Deem Osmotically Driven Dispense Pump and Related Components for Use in High Pressure Applications
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US20090312246A1 (en) 2005-08-19 2009-12-17 Amylin Pharmaceuticals, Inc. Uses of Glucoregulatory Proteins
WO2007024700A2 (en) 2005-08-19 2007-03-01 Amylin Pharmaceuticals, Inc. Exendin for treating diabetes and reducing body weight
WO2007056681A2 (en) 2005-11-04 2007-05-18 Smithkline Beecham Corporation Methods for administering hypoglycemic agents
US8039432B2 (en) 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
WO2007075534A2 (en) 2005-12-16 2007-07-05 Nektar Therapeutics Al, Corporation Polymer conjugates of glp-1
US20090209460A1 (en) 2005-12-16 2009-08-20 Amylin Pharmaceuticals, Inc. Compositions and methods for treating obesity and related metabolic disorders
WO2007084460A2 (en) 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
WO2007082889A1 (en) 2006-01-19 2007-07-26 N.V. Organon Kit for and method of assembling an applicator for inserting an implant
US20090012463A1 (en) 2006-01-19 2009-01-08 N.V. Organon Kit for and method of assembling an applicator for inserting an implant
US20090186817A1 (en) 2006-03-21 2009-07-23 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
US20090074734A1 (en) 2006-05-02 2009-03-19 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
WO2007133778A2 (en) 2006-05-12 2007-11-22 Amylin Pharmaceuticals, Inc. Methods to restore glycemic control
EP2020990A2 (en) 2006-05-30 2009-02-11 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2007140416A2 (en) 2006-05-30 2007-12-06 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
US8263736B2 (en) 2006-07-03 2012-09-11 Imperial Innovations Limited Compounds and their effects on feeding behaviour
US20080020016A1 (en) 2006-07-11 2008-01-24 Quest Pharmaceutical Services, Llc Pharmaceutical compositions for sustained release delivery of peptides
US20100144621A1 (en) 2006-08-04 2010-06-10 Dennis Kim Use of Exendins and Exendin Agonists and GLP-1 Receptor Agonists for Altering the Concentration of Fibrinogen
US20140378900A1 (en) 2006-08-09 2014-12-25 Intarcia Therapeutics, Inc. Osmotic Delivery Systems and Piston Assemblies for Use Therein
US8801700B2 (en) 2006-08-09 2014-08-12 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US20080091176A1 (en) 2006-08-09 2008-04-17 Alessi Thomas R Osmotic delivery systems and piston assemblies for use therein
US7879028B2 (en) 2006-08-09 2011-02-01 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US20110166554A1 (en) 2006-08-09 2011-07-07 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
US7682356B2 (en) 2006-08-09 2010-03-23 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US20100185184A1 (en) 2006-08-09 2010-07-22 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies for use therein
WO2008041245A2 (en) 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
US7632256B2 (en) 2006-10-24 2009-12-15 Mosler Theodore J Catheter gripping device
WO2008061355A1 (en) 2006-11-24 2008-05-29 Matregen Corp. Glp-1 depot systems, and methods of manufacture and uses thereof
US8101576B2 (en) 2006-12-13 2012-01-24 Imperial Innovations Limited Compounds and their effects on feeding behaviour
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
USD555589S1 (en) 2007-01-23 2007-11-20 Intec, Inc. Battery charger and game controller cradle
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
US20080208194A1 (en) 2007-02-13 2008-08-28 Christine Bickenbach Double cut shaver
US8262667B1 (en) 2007-02-23 2012-09-11 Holmed Corporation Multi-diameter implant forceps
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
WO2008134425A1 (en) 2007-04-27 2008-11-06 Cedars-Sinai Medical Center Use of glp-1 receptor agonists for the treatment of gastrointestinal disorders
US20090202481A1 (en) 2008-02-08 2009-08-13 Qps Llc Composition for Sustained Release Delivery of Proteins or Peptides
US9572889B2 (en) 2008-02-13 2017-02-21 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8926595B2 (en) 2008-02-13 2015-01-06 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20170079906A1 (en) 2008-02-13 2017-03-23 Intarcia Therapeutics Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20090202608A1 (en) 2008-02-13 2009-08-13 Alessi Thomas R Devices, formulations, and methods for delivery of multiple beneficial agents
US20090210019A1 (en) 2008-02-14 2009-08-20 Dennis Dong-Won Kim Treatment of excess weight by neural downregulation in combination with compositions
WO2009109927A2 (en) 2008-03-05 2009-09-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
US20090234392A1 (en) 2008-03-13 2009-09-17 Depuy Spine, Inc. Method for inserting a spinal fixation element using implants having guide tabs
US20110091527A1 (en) 2008-04-01 2011-04-21 Mosamedix B.V. Compositions and methods for reducing scar formation in wound healing
US20090254143A1 (en) 2008-04-04 2009-10-08 Tweden Katherine S Methods and systems for glucose regulation
WO2009143265A2 (en) 2008-05-20 2009-11-26 Charles Neill Stripping of heavier hydrocarbons from liquefied natural gas
WO2009143285A2 (en) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendins to lower cholestrol and triglycerides
US20100105627A1 (en) 2008-09-17 2010-04-29 Paul Salama Pharmaceutical compositions and related methods of delivery
US20160030337A1 (en) 2008-09-30 2016-02-04 Braeburn Pharmaceuticals Bvba Sprl Implantable device for the delivery of risperidone and methods of use thereof
US9078900B2 (en) 2008-09-30 2015-07-14 Braeburn Pharmaceuticals Bvba Sprl Implantable device for the delivery of risperidone and methods of use thereof
US20100094252A1 (en) 2008-10-14 2010-04-15 Medtronic, Inc. Subcutaneous delivery tool
WO2010045169A1 (en) 2008-10-14 2010-04-22 Medtronic, Inc. Subcutaneous delivery tool
US20160022582A1 (en) 2008-10-15 2016-01-28 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100092566A1 (en) 2008-10-15 2010-04-15 Alessi Thomas R Highly concentrated drug particles, formulations, suspensions and uses thereof
US20170119854A1 (en) 2008-10-15 2017-05-04 Intarcia Therapeutics, Inc. Highly concentrated drug particles, formulations, suspensions and uses thereof
NZ592113A (en) 2008-10-15 2012-04-27 Intarcia Therapeutics Inc Highly concentrated drug particles, formulations, suspensions and uses thereof
US20100298840A1 (en) 2009-05-22 2010-11-25 Schwartz Lyman D Phimosis Treatment Device and Method
US20100331878A1 (en) * 2009-06-25 2010-12-30 Carl Zeiss Surgical Gmbh Method and device for removing a balloon from a body cavity
USD638478S1 (en) 2009-07-06 2011-05-24 Performance Designed Products Llc Video game controller accessory
US8858621B2 (en) 2009-07-23 2014-10-14 Edwards Lifesciences Corporation Methods of implanting a prosthetic heart valve
WO2011011697A1 (en) 2009-07-23 2011-01-27 Sid Technologies, Llc Intradermal injection adapter
US20140257272A1 (en) 2009-08-07 2014-09-11 Ulthera, Inc. Handpiece and methods for performing subcutaneous surgery
US20130030417A1 (en) 2009-09-28 2013-01-31 Intarcia Therapeutics, Inc. Rapid Establishment and/or Termination of Substantial Steady-State Drug Delivery
US20110076317A1 (en) 2009-09-28 2011-03-31 Alessi Thomas R Rapid establishment and/or termination of substantial steady-state drug delivery
US20160354305A1 (en) 2009-09-28 2016-12-08 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8298561B2 (en) 2009-09-28 2012-10-30 Intarcia Therapeutics, Inc. Rapid establishment and/or termination of substantial steady-state drug delivery
US8815802B2 (en) 2009-12-16 2014-08-26 Novo Nordisk A/S GLP-1 analogues and derivatives
US20110152181A1 (en) 2009-12-22 2011-06-23 Eli Lilly And Company Oxyntomodulin peptide analogue
US20110152182A1 (en) 2009-12-22 2011-06-23 Eli Lilly And Company Oxyntomodulin peptide analogue
US20110306549A1 (en) 2010-06-09 2011-12-15 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonists to treat pancreatitis
USD669589S1 (en) 2010-08-31 2012-10-23 Koninklijke Philips Electronics N.V. Blood system cartridge
US8747412B2 (en) 2011-02-14 2014-06-10 Imds Corporation System and method for bone anchor removal
US20150057227A1 (en) 2011-02-16 2015-02-26 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US20170252409A1 (en) 2011-02-16 2017-09-07 Intarcia Therapeutics, Inc. Compositions, devices and methods of use thereof for the treatment of cancers
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20120303045A1 (en) 2011-05-26 2012-11-29 Derm Instruments & Innovations Llc Skin removal instrument
WO2013004983A1 (en) 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
US8190702B1 (en) 2011-08-16 2012-05-29 Edgecast Networks, Inc. Systems and methods for invoking commands across a federation
US20150001118A1 (en) 2011-09-16 2015-01-01 Golden Aluminum, Inc. Application of designs to portion of food container
USD678889S1 (en) 2011-10-04 2013-03-26 Avision Inc. Scanner docking station
GB2501400A (en) 2012-04-19 2013-10-23 Removaid As Tool for removing a subcutaneous implant
US20140058409A1 (en) 2012-04-19 2014-02-27 Removaid As Device for removing an item implanted underneath the skin
WO2013160347A1 (en) 2012-04-24 2013-10-31 Urogyn B.V. Bulking agent applicator for treating female urinary incontinence
US20130296661A1 (en) 2012-05-04 2013-11-07 Pacesetter, Inc. System and method for implanting a physiologic sensor assembly
US20150133791A1 (en) 2012-05-29 2015-05-14 National University Corporation Kochi University Artery visualization device and artery imaging device
WO2013184235A1 (en) 2012-06-04 2013-12-12 Medtronic, Inc. Transcutaneous implant tools, systems and methods
US20130324977A1 (en) 2012-06-04 2013-12-05 Medtronic, Inc. Transcutaneous implant tools, systems and methods
US20140058425A1 (en) 2012-08-27 2014-02-27 Amir Porat Manually operated surgical devices with operative portions formed of a see-through material
US9332995B2 (en) 2012-09-25 2016-05-10 Russo Inventions, Llc Bone-harvesting tool
US9241722B2 (en) 2012-10-08 2016-01-26 Warsaw Orthopedic, Inc. Surgical pin guide and methods of use
US20150297509A1 (en) 2012-11-19 2015-10-22 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions and methods of treatment thereof
US20140324067A1 (en) 2013-01-09 2014-10-30 Senseonics, Incorporated Subcutaneous tunneling and implantation tools for a disk-shaped sensor
US20140236162A1 (en) 2013-02-19 2014-08-21 Mark Barongan Apparatus for Removing Devices Implanted in the Body
US20160158577A1 (en) * 2013-07-25 2016-06-09 Bruno ESCARGUEL Medical device for radiotherapy treatment
USD750764S1 (en) 2014-04-08 2016-03-01 Bootz Manufacturing Company Shower pan
USRE46577E1 (en) 2014-06-05 2017-10-24 Deka Products Limited Partnership Enclosure for a peritoneal dialysis device
US20150359553A1 (en) 2014-06-16 2015-12-17 Med-El Elektromedizinische Geraete Gmbh Implant magnet insertion and removal tools
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US20160354115A1 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
USD789539S1 (en) 2015-07-09 2017-06-13 Spinal Surgical Strategies, Llc Fusion cage
USD789540S1 (en) 2016-01-29 2017-06-13 Veterinary Implants Direct, Llc. Orthopedic plate
US20170273706A1 (en) 2016-03-24 2017-09-28 A.M. Surgical, Inc. Compact endoscopic surgical device and method of use thereof
US20180009871A1 (en) 2016-05-16 2018-01-11 Intarcia Therapeutics Inc. Glucagon-receptor selective polypeptides and methods of use thereof
US20180368875A1 (en) * 2016-05-25 2018-12-27 Nalu Medical, Inc. Methods and systems for insertion and fixation of implantable devices
US20180185451A1 (en) 2017-01-03 2018-07-05 Intarcia Therapeutics, Inc. Methods Comprising Continuous Administration of a GLP-1 Receptor Agonist and Co-administration of a Drug

Non-Patent Citations (262)

* Cited by examiner, † Cited by third party
Title
"Open-label phase II study of omega interferon in previously untreated HCV infected patients - Mathias Plauth, Stadisches Klinikum, Dessau Germany; Helga Meisel, Institut fur Medizinische Virologie, Berlin Germany; Peter Langecker, Mark Moran, William Lang, Dennis Blachett, BioMedicines, Emeryville,", HEPATOLOGY, vol. 34, no. 4, 1 October 2001 (2001-10-01), pages A331, XP004716169, ISSN: 0270-9139
"Implantable infusion pumps: technology poised for takeoff," BBI Newsletter 17(12):209-211 (Dec. 1994).
"Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD, " Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release).
"Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
"Introduction to Antibodies", http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007).
"Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope", http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012).
Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
Adolf et al., "Antigenic structure of human interferon ω1 (Interferon αll 1): comparison with other human interferons," J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
Adolf et al., "Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN," Virology 175(2):410-471 (Apr. 1990).
Adolf et al., "Purification and characterization of natural human interferon ω1," J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf, "Human interferon omega-a review," Mult. Sclr. 1:S44-47 (1995).
Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
Akers, et al., "Formulation Design and Development of Parenteral Suspensions," Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharmaceutical Research, 10(7):945-953 (1993).
Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
ANDRX Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
Aulitzky, "Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," Journal of Clinical Oncology 7(12):1875-1884 (1989).
Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," Bioconjugate Chemistry 12(2):195-202 (2001).
Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," J. Pharm. Sci., 85(9):908-914 (1996).
Bakhtiar et al, "Taking Delivery," Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
Balkwill,F., "Interferons," Lancet 1(8646):1060-1063 (May 1989).
Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," Biology of Reproduction, 28(1): 186-195 (1983).
Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," Hepatology 33(2):419-423 (Feb. 2001).
Bell et al, "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," Nature 302:716-718 (1983).
Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," Int. J. Radiat. Biol. 67(1):57-64 (1995).
Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," Euro. J. Pharm. Sci. 2(4):271-279 (1994).
Bolinger et al., "Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders," Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden et al., "Second-generation interferons for cancer: clinical targets," Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
Boué´et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from Pichia pastoris," J. Interferon & Cytokine Res. 20:677-683 (2000).
Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
Buckwold et. al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," J. Chem. Physics 104(20):8082-8095 (1996).
CAS Number: 56-81-5 (Nov. 16, 1984).
Cha and Pitt, "A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules," Journal of Controlled Release, 7: 69-78 (1988).
Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," Journal of Controlled Release, 8: 259-265 (1989).
Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," Pharm. Tech. 20(1):80-84 (1996).
Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," Chem. & Physics of Lipids 1(5):445-475 (1967).
Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
Clark et al., "The diabetic Zucker fatty rat," Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharmaceutical Research, 8(6): 713-720 (1991).
Condino-Neto, "Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," Blood 95(11):3548-3554 (Jun. 2000).
Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," Journal of Microencapsulation, 9(2): 153-166 (1992).
Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," J. Pharm. Sci. 91:388-395 (2002).
Croxatto, "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant," Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8.
Darney, "Subdermal progestin implant contraception," Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," BioPharm, 2(11):44-51 (1999).
Dash et al., "Therapeutic applications of implantable drug delivery systems," Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570 ).
Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," J. Am. Chem. Soc. 116(21):9420-9422 (1994).
Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," J. Interferon Res. 8:717-725 (1988).
Efendic et al., "Overview of incretin hormones," Horm. Metab. Res., 36(11-12):742-746 (2004).
Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," Life Sci., 55(8):629-634 (1994).
Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," Cancer 89(3):597-603 (Aug. 2000).
Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," J. Biol. Chem., 267(11):7402-7405 (1992).
Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from Heloderma horridum venom," J. Biol. Chem., 265(33):20259-20262 (1990).
Eppstein et al., "Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor," PNAS USA 82:3688-3692 (1985).
Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," Proc.-Conf. Colloid Chem. 193-196 (1993).
Erowid,"Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages.
Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," Vaccine 14(9):879-885.(1996).
Fang et al., "The impact of baseline liver histology on virologic response to interferon α-2b±p ribavirin therapy in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," J. Nutritional Biochem. 4(1):630-634 (1993).
Ferenci et al, "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α," Lancet 356(9223):41 (Jul. 2000).
Franchetti et al., "Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues, Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," J. Medicinal Chem. 38(19):3829-3837 (1995).
Fujii et al "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)." Int'l J. Pharmaceutics 234(1-2);121-128 2002).
Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001).
Fujii et al., "Effect of phosphatidylehohne on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001).
Gan to Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
Gao et al., "Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys. And Humans," Drug Metabolism and Disposition, vol. 40, No. 5, pp. 990-997 (2012).
Gappa et al., "Juvenile laryngeal papillomatosis-a case report," Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
GAPPA M; FREIHORST J; SEIDENBERG J; VOLLRATH M; VON DER HARDT H: "�JUVENILE LARYNGEAL PAPILLOMATOSIS--A CASE REPORT�", PNEUMOLOGIE, THIEME, STUTTGART, DE, vol. 45, no. 11, 1 November 1991 (1991-11-01), DE, pages 936 - 938, XP009079028, ISSN: 0934-8387
Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
Georgios, et al., "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers", Advances in Therapy, Health Communications, Metuchen, NJ, US, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661.
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Diabetologia 27:599-600 (1984).
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Disbetologia 27:599-600 (1984).
Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
Glumetza Brochure 2009, 13 Pages.
Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," J. Biol. Chem., 268(26):19650-19655 (1993).
Gonzales et al., "Randomized controlled trial including an initial 4-week ‘induction’ period during one year of high-dose interferon α-2B treatment for chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," Salud Publica Mex 55:462-468 (2013).
Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995).
Grant et al., "Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," J. Med. Virol. 61(4):439-442 (Aug. 2000).
Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," N. Engl. J. Med., 326(20):1316-1322 (1992).
Hageman, "The Role of Moisture in Protein Stability, " Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).
Hauck, "Engineer's Guide to Plastics," Materials Engineering 5(72):38-45 (Jul. 17, 1972).
Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," New England J. Med. 343(23):1673-1680 (2000).
Heim et al., "Intracellular signaling and antiviral effects of interferons," Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinol., 115:2176-2181 (1984).
Hellstrand et al., "Histamine and cytokine therapy," Acta Oncol. 37(4):347-353 (1998).
Hellstrand et al., "Histamine and the response to IFN-α in chronic hepatitis C," Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
Henry et al. (2014) "Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes," Journal of Diabetes and Its Complications, 28:393-398.
Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010).
Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," J. Toxicol. Sci., 18(3):1-9 (1993).
Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," International Journal of Pharmaceutics, 146(1):81-92 (1997).
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999).
Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia 11 Suppl 5:S47-S51 (Dec. 1997).
Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," Am. J. Clin. Oncol. 18(1):27-31 (1995).
IFNB Multiple Sclerosis Study Group, "Interferonβ-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43(4):655-667 (Apr. 1993).
Implanon_Prescribing Information. Manufactured for Merck Sharp Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016.
Isaacs et al., "Virus interference. I. The interferon," Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8):911-917 (1998).
Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," J. Microencapsulation 17(3):343-362 (2000).
Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
Johnson et al., "How interferons fight disease," Sci. Am. 270(5):68-75 (May 1994).
Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," The Oncologist 12(9):1143-1150 (2007).
Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0/8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," Journal of Colloid and Interface Science 184(1):227-235 (1996).
Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," J. Clin. Oncol. 14(1):7-17 (1996).
Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ," Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
Knepp et al, "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," J. Pharm. Sci. Tech. 50(3):163-171 (1996).
Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," Pharma. Res. 15(7):1090-1095 (1998).
Knobler et al., "Systemic α-interferon therapy of multiple sclerosis," Neurology 34(10):1273-1279 (Oct. 1984).
Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon," Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS," Neurology 54(1):193-199 (Jan. 2000).
Krown et al., "Interferons and interferon inducers in cancer treatment," Semin. Oncol. 13(2):207-217 (1986).
Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon-ω" J. Interferon Res. 14:57-59 (1994).
Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication," J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
Larsson, "Stability of emulsions formed by polar lipids," Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
Lee and Timasheff, "The stabilization of proteins by sucrose," J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
LEE W M: "THERAPY OF HEPATITIS C: INTERFERON ALFA-2A TRIALS", HEPATOLOGY, vol. 26, 1 September 1997 (1997-09-01), pages 89S - 95S, XP000981288, ISSN: 0270-9139, DOI: 10.1002/hep.510260716
Lee, "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
Li et al. ("Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," Journal of Controlled Release, 37: 199-214 (1995).
Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," Neurology. 46:907-911 (1996).
Luft et al., "Electro-osmotic valve for the controlled administration of drugs," Med. & Biological Engineering & Computing 45-50 ( Jan. 1978) (non-English with English abstract).
Lukaszewski et al., "Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," J. Virol. 74(11):5006-5015 (Jun. 2000).
Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," J. Pharm. & Pharmacol. 49(1):16-21 (1997).
Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results," Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
Magnuson et al "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," Protein Expression & Purification 7:220-228 (1996).
Malley et al., "Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration," Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
Manning et al, "Stability of protein pharmaceuticals," Pharm. Res. 6(11):903-918 (1989).
Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
MARINCOLA FRANCESCO M; WHITE DONALD E; WISE ALLISON P; ROSENBERG STEVEN A: "COMBINATION THERAPY WITH INTERFERON ALFA-2A AND INTERLEUKIN-2 FOR THE TREATMENT OF METASTATIC CANCER", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 13, no. 5, 1 January 1995 (1995-01-01), US, pages 1110 - 1122, XP009078965, ISSN: 0732-183X
Massey, "Interaction of vitamin E with saturated phospholipid bilayers," Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," Journal of Controlled Release, 3: 103-117 (1986).
McHutchison et al., "Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998).
Mehta, et al.,"Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," Journal of Controlled Release, 41: 249-257 (1996).
Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12)," J. Immunother. 23(3):369-378 (May-Jun. 2000).
Milella et al., "Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection," Liver 13(3):146-150 (Jun. 1993).
Mohler, "Primer on electrodeposited coatings," Materials Engineering 5:38-45 (1972).
Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," Int. J. Peptide Protein Research, 40:333-343 (1992).
Morgan, "Structure and Moisture Permeability of Film-Forming Poloyers," Ind. Eng. Chem. 45(10):2296-2306 (1953).
Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," J. Clinical Oncol. 19(5):1312-1319 (2001).
Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," Diabet. Med., 15(11):937-945(1998).
Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," Science 282:103-107 (Dec. 1998).
Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Nexplanon_Presscribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright ©Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects," Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," Drug Discovery Today 10(10):703-710 (May 15, 2005).
Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration," Eur. J. Pharm. Sci. 13(4):393-401 (2001).
Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages.
Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
Ortiz et al., "A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids," Biochim et Biophys Acta 898(2):214-222 (1987).
Palmeri et al., "5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327-330 (Oct. 1990).
Panitch, "Interferons in multiple sclerosis," Drugs 44(6):946-962 (Dec. 1992).
Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study," Acta. Neurol. Scand. 100:283-289 (1999).
Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," Neurology 43:662-667 (1993).
Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," Nature, 282:260-266 (1979).
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," ILAR Journal, 32(3):16-19 (1990).
Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973).
Plauth et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
Plauth et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
PLAUTH MATHIAS MATHIAS, ET AL: "Open-label study of omega interferon in previously untreated HCV-infected patients.", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 36, no. Supplement 1, 1 April 2002 (2002-04-01), AMSTERDAM, NL, pages 125, XP002511882, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(02)80444-5
Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," J. Biol. Chem., 273(16):9778-9784 (1998).
Poynard et al., "Is an ‘a la carte’ combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," Hepatology 31(1):211-218 (Jan. 2000).
Poynard et al., "Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," Lancet 352(9138):1426-1432 (Oct. 1998).
Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," Rev. Diabet. Stud., 5(2):73-94 (2008).
Probuphine _Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987).
Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," US Endocrinology 7(2):104-109 (2011).
Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," Pharm. Res. 14(2):119-127 (1997).
Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial," Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
Roberts et al., "The Evolution of the Type I Interferons 1," J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971).
Rogers et al., "Permeability Valves," Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," Transplantation 48(4):554-558 (1989).
Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," Endocrinol. 148(12):6054-61 (Dec. 2007).
Roth et al., "High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," Acta Oncol. 38(5):613-617 (1999).
Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," Pharmaceutical Research, 13(3): 360-367 (1996).
Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," Pharmaceutical Research, 5(1): 21-30 (1988).
Schepis et al. (2001) "Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection," Hepatology, 33(2):333-338.
Schepp et al., "Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2," Eur. J. Pharmacol., 269(2):183-191 (1994).
Schering Corp., Intron® A for Injection, 6 pages (2001).
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
Schmalfub et al., "Modification of drug penetration into human skin using microemulsions," J. Controlled Release 46(3):279-285 (1997).
Sen et al., "The interferon system: a bird's eye view of its biochemistry," J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
Shiffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," Ann. Int. Med. 132(7):517-524 (Apr. 2000).
Shire et al., "Challenges in the Development of High Protein Concentration Formulations," J. Pharm. Sci. 93:1390-1402 (2004).
Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a," Neurology 55(2):185-192 (Jul. 2000).
Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," Metabolism, 47(11):1315-1324 (1998).
Sulkowski et al., "Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," Biodrugs 16(2):105-109 (2002).
Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," Endocrinology, 141(6): 1936-1941 (2000).
Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," Blood 98(6):1708-1713 (2001).
Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," Endocrinology 146(9):3748-56 ( Sep. 2005).
Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," Int. J. Cancer 87(5):741-749 (Sep. 2000).
Taylor et al., "Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes", Horm Metab Res 37: 627-632 (2005).
Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," Journal of Controlled Release 43(1):9-22 (1997).
Tong et al., "Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," Hepatology 26(6):1640-01645 (Dec. 1997).
Touza Rey et al., "The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to Aspergillus fumigatus," Ann. Med. Int. 17(2):86-87 (Feb. 2000).
Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro." Biomaterials. 20(11:): 1057-1062 (1999).
Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," PNAS USA, 90(5):1992-1996 (1993).
Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," J. Pharm. Sci. 86(5):603-7 (May 1997).
Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," J. Biomed. Materials Res. 17:931-943 (1983).
Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
Wang et al, "Parenteral formulations of proteins and peptides: stability and stabilizers," J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
Wang et al., "Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," Eur. J. Biochem. 267(21):6362-6368 (2000).
Wang et al., "Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines," Archives of Biochem. & Biophys. 377(2):304-314 (2000).
Wang et al., "The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine," Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (Apr. 15, 2011).
Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)," Diabetes, 48(5):1026-1034 (1999).
Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C," Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
Yu et al., "Glucagon-like peptide 1 based therapy for type 2 diabetes", World Journal of Pediatrics vol. 4, No. 1, Feb. 1, 2008, pp. 8-13.
Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," J. Pharm. Sci. 85(4):396-401 (1996).
Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2′,3′-dideoxycytidine," Antivir. Res. 11(3):147-0160 (Apr. 1989).
Zein, "Interferons in the management of viral hepatitis," Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover," Hepatology 28(1):245-252 (Jul. 1998).
Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," New Engl. J. Med. 343(23):1666-1672 (2000).
Zhang et al, "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," Pharm. Res. 12(10):1447-1452 (1995).
Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," Current Physician 2(12):45-46 (1997).
Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," J. Clinical Pediatrics 14(2):83-84 (1996).
Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," Beijing Med. J. 13(2):80-81 (1998).
Ziesche et al., "A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD933219S1 (en) * 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly

Also Published As

Publication number Publication date
CA175047S (en) 2017-07-31
AU201710853S (en) 2017-02-28
JP1593290S (en) 2017-12-18
JP1596822S (en) 2018-02-05
AU201616506S (en) 2017-02-28
AU201710849S (en) 2017-02-28
AU201710850S (en) 2017-02-28
JP1596821S (en) 2018-02-05
CA171754S (en) 2017-07-31
USD912249S1 (en) 2021-03-02
AU201710852S (en) 2017-02-28
CA175048S (en) 2017-07-31
AU201710851S (en) 2017-02-28

Similar Documents

Publication Publication Date Title
USD960372S1 (en) Prosthetic valve and holder
USD808395S1 (en) Device case
USD842489S1 (en) Massage tool
USD806879S1 (en) Hearing device
USD835600S1 (en) Sound machine
USD813203S1 (en) Hand held controller
USD806805S1 (en) Robot
USD874776S1 (en) Trash receptacle
USD985773S1 (en) Three dimensional mastopexy implant
USD855700S1 (en) Drawing tool
USD873932S1 (en) Robot
USD835508S1 (en) Jar
USD880159S1 (en) Device case
USD833636S1 (en) Myofascial release tool
USD829686S1 (en) Headphones
USD995326S1 (en) Workpiece holding square
USD871885S1 (en) Centering dovetail vise
USD852507S1 (en) Device case
USD877726S1 (en) Device case
USD883491S1 (en) In-ear device
USD802412S1 (en) Carton
USD868518S1 (en) Bench
USD894385S1 (en) Orthopedic tool
USD845362S1 (en) Holesaw
USD840199S1 (en) Cutting boards

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY